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ABSTRACT 
In higher eukaryotes, a considerable number of the expressed transcripts do not 
code for proteins. These non-coding RNAs (ncRNA) play different functions in cells. 
Some of them have been characterized as regulatory RNA molecules like 
microRNAs, but the functions of many other ncRNAs are not yet known. 
The human HI9 non-coding RNA is a paternally imprinted and maternally 
expressed gene mapped to chromosome l i p 15.5. It is abundantly expressed in 
placenta, fetal tissues and silenced in most adult tissue, but overexpressed in some 
cancer cells such as mammary epithelial cancers and hepatocellular cancers. 
Although intensive research has been carried out for the mechanism of genomic 
imprinting of H19-Igf2 locus in the past decade, the function of HI 9 RNA in cancer 
cells and its underlying molecular mechanism is still unclear. In this study, the 
function of HI9 in the regulation of MDRl expression in human hepatocellular 
carcinoma HepG2 cells was investigated. 
MDRl is one of the genes contributing to multi-drug resistance (MDR) 
phenomenon. Overexpression of both MDRl and HI9 was observed in a 
doxombicin-resistant HepG2 subline. By employing RNA interference (RNAi) 
technique, knockdown of HI9 RNA resulted in reduced expression of MDRl in 
HepG2 cells. Regulation of MDRl expression by HI9 might depend on its RNA 
binding protein, IMPl, since knockdown of IMP 1 also reduced MDRl expression. 
Meanwhile, knockdown of another HI9 RNA binding protein, PTB, increased 
MDRl expression and drug-induced apoptosis. The results from RNAi experiments 
suggested that HI9 might regulate MDRl expression by interacting with its RNA 
binding proteins. By using RNA-affinity chromatography, new members of HI9 
RNA binding proteins were identified. Data from the present study might help to 





















耐受性的 HepG2 亞系細胞（Doxombicin-resistant HepG2 subline)中，MDR1 與 
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1.1 Non-coding RNAs in transcriptional output 
In human, around 97-98% of the transcriptional product does not code for 
protein. These non-coding RNAs (ncRNA) include spliced introns, small nucleolar 
RNAs (snoRNA), pseudogenic transcripts, microRNA precursor transcripts as well 
as some processed mRNA-like non-coding RNAs (Figure 1.1) (Mattick 2001). 
Among them, intronic RNA is a big class of ncRNA that constitutes for about 
95% of the primary protein-coding transcripts (Lander et al. 2001; Venter et al. 2001). 
Small nucleolar RNA, which is originally identified in assisting rRNA processing 
and ribosome subunits assembling, can also regulate other RNAs including snRNAs 
(small nuclear RNA) and mRNAs (Bachellerie et al. 2002; Kiss et al. 2004). In 
human, there are over 300 different snoRNAs identified so far (Griffiths-Jones et al. 
2005; Liu et al. 2005), many of them are derived from introns of pre-mRNA or by 
cleavage of unspliced primary transcripts (Bachellerie et al. 2002; Kiss 2002). Some 
ncRNAs are actually antisense to the functional coding mRNA in both prokaryotes 
and mammals (Rosok & Sioud 2004; Yachie et al. 2006; Yelin et al. 2003). 
Interestingly, some antisense RNAs are known to be transcribed from pseudogenes, 
which are thought to be non-functional (Chan et al. 2006). A new class of small 
regulatory RNA, microRNA (miRNA), was discovered in recent years. The 
functional mature miRNAs are processed from its precursor RNA by specific 
2 
enzymes (Murchison & Hannon 2004). While most of the discovered miRNA are 
derived from intergenic regions, some are derived from coding mRNA 
(Lagos-Quintana et al. 2002; Lau et al. 2001). Since systematic classification of 
ncRNA has not been established, some ncRNAs are hard to be classified because of 
their uncertainty in functions. Genome wide analysis of transcriptome revealed a 
large number of ncRNAs. Many of the ncRNAs are processed (RNA splicing, 
polyadenylation etc) just like mRNA, but they generally lack a substantial open 
reading frame (ORP) (Okazaki et al. 2002). 
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Figure 1.1 A revised view for the flow of the genetic information in higher 
eukaryotes. Primary transcripts may be (alternatively) spliced and further processed 
to produce a range of protein isoforms and/or ncRNAs of various types, which are 
involved in complex networks of structural, functional and regulatory interactions, 
(adopted from Mattick et al. 2003) 
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1.2 Diverse functions of non-coding RNAs 
In higher eukaryotes, ncRNAs are found to participate in many complex genetic 
phenomena such as co-suppression, transcriptional and post-transcriptional gene 
silencing, RNA interference, RNA-directed DNA methylation and probably 
transcription. Annotate 
Epigenetic gene regulation in eukaryotes is usually directed by DNA 
methylation. RNA-directed DNA methylation has been found in plants (Wassenegger 
2000), in which double-stranded RNA (dsRNA) transcripts direct the localization of 
DNA methyltransferases to specific targets in the genome (Aufsatz et al. 2002). 
Furthermore, loss of the expression of a C/D snoRNAs confers an imprinting disease 
Prader-Willi syndrome (Cavaille et al. 2002; Gallagher et al. 2002). The involvement 
of ncRNAs in transcription is implicated by the ability of some common 
transcription factors to bind RNA or RNA-DNA hybrids. For example, zinc finger 
protein Spl shows greater affinity for RNA-DNA hybrids than dsDNA (Shi & Berg 
1995). Some ncRNAs are found to be necessary for transactivation. Examples are 
SRA (steroid receptor RNA activator) in steroid receptor transactivation and 7SK 
RNA in c-myc activation (Krause 1996; Lanz et al. 1999; Lanz et al. 2002). It is 
therefore proposed that trans-acting ncRNAs may act to recruit transcription factors 
to sequence-specific locations in the chromosome (Mattick 2003). And this can 
5 
explain why most transcriptional factors have relatively loose consensus binding 
sites that are commonly found in many places of the genome. Other RNA-directed 
genetic regulations include co-suppression in plants (Lindbo et al. 1993) and RNA 
interference in animals; both processes are mediated by dsRNA (Fire et al. 1998; 
Montgomery et al. 1998). 
1.3 HI9: imprinted non-coding RNA 
Functions of ncRNAs are diverse. Some have been intensively studied, while 
many of them are still unknown or thought to be functional. Among the various types 
of ncRNAs identified so far, a class of ncRNA is expressed from the imprinted genes. 
One of the maternally expressed imprinted genes, HI9，was identified as non-coding 
RNA transcribed from an imprinted cluster on the human chromosome l ip 15 (Zhang 
& Tycko 1992). This region has been associated with tumor suppressor activity. The 
expression pattern of HI9 RNA in some cancer cells is different from that in the 
neighboring non-malignant cells (Ariel et al. 1997; Ariel et al. 2000). Therefore, HI9 
was proposed to be a tumor suppressor gene (Han et al. 1996). However, more and 
more evidences support the carcinogentic role of this RNA in promoting tumor 
formation (Lottin et al. 2002a). While the function of HI9 RNA is yet controversial, 
the mode of regulation mediated by HI 9 is not yet explored from years. 
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1.4 Objective 
The objective of this study is to examine the regulatory function of HI 9 RNA in 
cancer cells. More specifically, the present study was focused on the function of HI 9 
RNA in the regulation of MDRl-related drug resistance in human hepatocellular 
carcinoma HepG2 cells. 
Differential expression of non-coding HI9 RNA in cancer cells might confer a 
novel role of this RNA in cancer biology. It was observed initially that this RNA was 
overexpressed in a drug-resistant HepG2 subline. Therefore, in order to investigate 
the relationship between HI 9 RNA and MDRl-related drug resistance, RNA 
interference was employed to knock down HI9 expression. And the effect of HI9 
knockdown on drug resistance was discussed in Chapter 2. 
In Chapter 3, we started to explore the possibility of HI 9 RNA binding proteins 
in regulating H19-related drug resistance. Similarly, RNA interference technique was 
used to knock down the two potential HI9 RNA binding proteins and the effect of 
their knockdown on H19-related drug resistance was investigated. 
It is hypothesized that RNA-protein interactions play a critical role in the 
functions of ncRNAs. In order to study the mechanism of H19-associated gene 
regulation, classical RNA-protein interactions assays that study the interactions of 
HI9 RNA with cellular proteins were performed. Finally, attempts were made to 
7 
isolate other potential HI9 RNA binding proteins by using RNA affinity 
chromatography method, in combination with mass spectrometry. This will be 
discussed in Chapter 4. 
To our surprise, during the study of the gene regulation by HI 9 RNA, we found 
that a putative HI9 RNA binding protein, the polypyrimidine tract-binding protein 
(PTB), was involved in the regulation of apoptosis, apart from regulating HI9. 
Therefore in Chapter 5，the role of PTB in apoptosis was discussed. 
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CHAPTER TWO 
The Role of H19 RNA in MDRl Expression of 
Human Hepatocellular Carcinoma HepG2 Cells 
9 
2.1 Introduction 
2.1.1 H19-Igf2 locus as a model for genomic imprinting 
Since its first report as early as in 1984 (Pachnis et al. 1984; Pachnis et al. 1988), 
HI9 has been extensively studied as a model for genomic imprinting. Genomic 
imprinting refers to allele-specific expression of genes according to their origins of 
parental chromosomes. For instance, HI9 is an imprinted gene that is only 
maternally expressed, but is silenced in the paternal chromosomes due to methylation 
in the upstream regulatory element. Therefore, DNA methylation in ICR (imprinting 
control region) or DMR (differentially methylated region) forms the basis of 
genomic imprinting that controls the state (either activated or silenced) of 
downstream imprinted genes. 
HI9 and Igf-2 are two closely related genes that reside on human chromosome 
l lp l5 . The imprinting pattern between HI9 and Igf-2 is opposite: HI9 is paternally 
imprinted while Igf-2 is maternally imprinted. These two genes are 90kb apart. 
Within this intergenic region, there are a number of regulatory elements that control 
the imprinting of the H19-Igf2 cluster (Figure 2.1) (Gabory et al. 2006). Deletion of 
the regulatory elements in mouse leads to loss of imprinting, i.e. the normally 
monoallelic expressed HI9 or Igf-2 gene becomes biallelic expressed (Srivastava et 
al. 2000; Thorvaldsen et al. 1998). Within the past fifteen years, a lot of work has 
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Figure 2.1 Common enhancers of the HI9 and Igf2 genes. (A) Distances in kb 
from the HI9 gene transcription start site. (B) Igf2 / H19 locus and enhancer 
positions. CS: human/mouse conserved sequences. CS3 and 4 are endodermal 
enhancers (Endo), CS9 is a mesodermal enhancer (Meso, Mu: skeletal muscle, To: 
tongue, He: cardiac muscle, Ki: kidney, Lu: lung). HUC: HI9 Upstream Conserved 
regions, HUC 1 and 2 are mesodermal enhancers. The Imprinting Control Region is 
composed of a differentially methylated region (DMR) and a silencer element (sil). 
The DMR can bind the CTCF insulator protein and the silencer is able to repress 
HI9 paternal expression. (C) Model for HI9 and Igf2 expression. On the paternal 
allele (Pat), Igf2 is activated by the different mesodermal and endodermal 
enhancers but the enhancers downstream of HI9 are blocked by the CTCF 
insulation on the maternal allele (Mat). HI9 is activated by HUC and the 
downstream enhancer on the maternal allele but repressed by the silencer on the 
paternal allele, (adopted from Gabory A. et al, 2006) 
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been done in the study of the mechanism of imprinting within this locus. It is now 
clear that the CpGs islands between -4 and - 2 kb upstream of HI9 designate the 
reciprocal imprinting pattern (Tremblay et al. 1995; Tremblay et al. 1997). When this 
region is differentially demethylated in the maternal chromosome, binding of a zinc 
finger protein called CTCF (CCCTC binding transcription factor) can insulate and 
silence the expression of Igf-2 gene by inhibiting the interaction of the downstream 
enahancers with the Igf2 promoters. On the contrary, methylation of this region in the 
paternal chromosme prevents recruitment of CTCF and thus, activates the upstream 
Igf-2 gene but inactivates the downstream HI9 (Bell & Felsenfeld 2000; Hark et al. 
2000; Kanduri et al. 2000; Szabo et al. 2000). HI9 is inactivated because its 
promoter is methylated once the CTCF-binding region is methylated, perhaps 
through a spreading mechanism (Figure 2.IB, C) (Szabo et al. 2004). This model 
explains the reciprocal expression relationship of the imprinted HI 9 and Igf2 genes. 
2.1.2 HI9 as a non-protein coding regulatory RNA 
Non-protien coding RNA, or non-coding RNA refers to those transcripts that 
their genetic information is not coding for amino acid sequence of proteins. This type 
of RNA may exist as regulatory molecules that possess different functions. 
The mature transcript of HI9 is 2.3 kb long. It has five spliced exons, a 5' end 
12 
cap site and a polyadenylation signal sequence near the 3’ end. Sequence analysis of 
the mature HI9 RNA reveals the presence of 35 small open reading frames (ORF). 
The longest ORF, which is located within the first exon, can encode a hypothetical 
protein of 132 amino acids. Brannon et al cloned and expressed this ORF in E. coli 
and used this recombinant protein to raise polyclonal antibodies. Although they have 
successful used the "anti-H19" antibodies to detect the in vitro translated HI9 
product, they failed to detect any endogenous HI9 product in a variety of 
H19-expressing cell lines or transfected cell lines (Brannan et al. 1990). It is 
therefore believed that HI9 exists as a non-coding RNA. To date, no protein product 
of this gene has been reported. 
2.1.3 Controversial roles of H19 RNA 
Although it is generally accepted that HI9 functions as a regulatory RNA, the 
function of this gene is still controversial. To study the function of HI9, targeted 
deletion of this gene was produced in mice. While all the HI9 knockout mice were 
found to be viable, overgrowth phenotype was observed. This is linked to the loss of 
imprinting in the adjacent Igf2 gene on the maternal chromosome. It is therefore 
suggested that HI9 locus, but not the HI9 transcript, controls the in cis Igf2 
expression (Leighton et al. 1995; Ripoche et al. 1997). 
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Another role of HI9 in development is implicated by the observation that this 
gene is highly expressed during embryogenesis. However, since HI9'^' mice are 
survived as normal H19+Z+ wild type, the role of HI9 in development is still unclear. 
In vitro experiments showed that HI9 RNA had a trans effect on the level of Igf2 
expression (Wilkin et al. 2000). What is more, nutrient supply such as methionine, 
threonine and glycine during pregnancy will alter DNA methylation and hence the 
imprinting status of H19-Igf2. Khosla et al performed experiment to culture mouse 
blastocysts in the presence of serum and then the embryos were transferred to 
recipient mothers. The fetuses showed a reduced body weight at day 14 and 
decreased HI9 and Igf2 expression, due to the increased ICR methylation (Khosla et 
al. 2001). Therefore, the role of H19 in development may be linked to Igf2 both in 
epigenetic approach (due to alteration of methylation in ICR) and/or genetic 
approach (due to the functional activities of the gene itself). 
HI9 has also been implicated to function as an oncofetal gene, based on the 
observation that it is abundantly expressed in placenta, silenced in normal adult 
tissues except muscle cells, re-expressed in some cancer cells (Milligan et al. 2000). 
Oncogenic properties are supported by evidences that overexpression of ectopic HI9 
gene: i) enhances the tumorigenic properties of breast cancer cells (Lottin et al. 
2002a; Lottin et al. 2002b); ii) upregulates genes that contribute to tumor invasion 
14 
and angiogenesis (Ayesh et al. 2002; Ghana et al. 2002). 
In addition to the oncogenic properties proposed, HI9 has also been implicated 
to act as a tumor suppressor gene. In Wilms' tumours, IGF2 was biallelically 
expressed and HI9 was fully repressed, with the HI9 DMR being hypermethylated 
in both alleles (Dao et al. 1999; Frevel et al. 1999). Recent reports indicated that 
microdeletion in the HI9 DMR of Beckwith-Wiedemann syndrome patients lead to 
loss imprinting with biallelic expression of Igf2 and silencing of HI9 (Prawitt et al. 
2005; Sparago et al. 2004). 
2.1.4 Novel role of H19 RNA in drug resistance 
While whether HI9 has a specific function or it is just a by-product of 
transcription remains controversial, an intriguing role of this non-coding RNA was 
implicated by its overexpression in a multi-drug resistance (MDR) MCF-7 subline 
(Doyle et al. 1996). This MDR-related HI9 upregulation phenomenon is also 
observed in another human cancer cell line, HepG2. The underlying mechanism of 
HI9 overexpression in MDR cancer cells is unknown, possibly due to epigenetic 
changes of the HI9 ICR elements. Nevertheless, the hypothesis that HI9 expression 
confers drug resistance is proposed in this study. The study of the downstream HI9 
function might provide evidences to explain why this gene is coordinately and 
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differentially expressed, and solve the puzzle of non-coding RNA mediated gene 
regulation. 
16 







Ammonium persulphate (APS) Sigma 
Aprotinin Sigma 
BCA protein assay PIERCE 
Bromochloropropane (BCP) Molecular Research Center 
Benchmark Prestained protein marker Invitrogen 
Bromophenol blue Sigma 
Copper II sulphate 5H2O Sigma 
Diethyl pyrocarbonate (DEPC) Sigma 
Dimethyl sulfoxide (DMSO) Fisher Scientific 
Dulbecco's Modified Eagles's Medium (DMEM) Invitrogen 
dNTP Invitrogen 
Doxorubicin (DOX) Sigma 
ECL Western Blotting Detecting Reagents Amersham Biosciences 
Ethanol Scharlau 
Ethidium bromide Sigma 
Fetal bovine serum (FBS) GIBCO 
G418 sulphate Calbiochem 
Glycerol Sigma 
Glycine Invitrogen 
Immobiline-P transfer membrane Millipore 
Isopropanol MERCK 
Leupeptin Amersham Biosciences 
L-glutamate Invitrogen 
Lipofectamine 2000 reagent Invitrogen 
Magnesium chloride Sigma 
Methanol BDH Laboratory Suppliers 
M-MLV reverse transcriptase Promega 
MTT Sigma 
17 
Oligo(dT) primer Invitrogen 
Phenylmethysulfonylfluorid (PMSF) Boehringer Mannheim 
pSilencer 2.1-U6 vector Ambion 
Sodium dodecyl sulphate (SDS) Invitrogen 
Sodium ortho-vanadate Sigma 
T4 DNA ligase Invitrogen 
Taq DNA polymerase Promega 
Taxol / paclitaxel Sigma 
TEMED Invitrogen 
Tris base USB 
Triton X-100 Boehringer Mannheim 
Trizol reagent Invitrogen 
Tween 20 Sigma 
Antibodies Company/Supplier 
anti-p-actin antibody Sigma 
anti-MDRl/P-glycoprotein antibody Oncogene 
anti-Mouse IgG HRP-conjugate Zymed 
anti-Rabbit IgG HRP-conjugate Zymed 
Culture wares Company/Supplier 
96-well flat bottom culture plate Nunc 
3 5-mm culture dish TPP 
60-mm culture dish TPP 
100-mm culture dish Iwaki 
Instruments/Equipments Company/Supplier 
3-MM filter paper Whatman 
Film cassette Kodak 
Gammacell 3000 Elan Irradiator MDS Nordion 
GeneAmp PGR system 9700 Applied Biosystems 
Microplate reader Molecular Device 
Mini-Protean II electrophoresis apparatus Bio-Rad 
Trans-Blot SD semi-transfer cell Bio-Rad 
UV transilluminator UVP 
X-ray film Fuji 
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2.2.2 Methods 
2.2.2.1 Cell culture 
The human hepatocellular carcinoma HepG2 cells were cultured in Dulbecco 
modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum and 5 
mM L-glutamate in 37°C humidified 10% CO2 incubator. The HepG2 sublines stably 
transfected with pSilencer 2.1-neo vector were cultured under the same condition 
except that 300 |j,g/ml G418 was added to the medium. 
2.2.2.2 Plasmid construction and stable cell transfection 
DNA oligos for shRNAs targeting 5'- CATCAAAGACACCATCGGA-3‘ of 
H19 or 5'-GGTTATGTACAGGAACGCA-3‘ of GFP mRNA were chemically 
synthesized by Techdragon Inc. The complementary oligos were annealed to form a 
dsDNA with a 5，-end BamHI and a 3'-end Hindlll overhang restriction recognition 
sites. The DNA cassette was ligated into a mammalian expression vector pSilencer 
2.1-U6 (Ambion) and the sequence of the shRNA-expressing insert was confirmed 
by DNA sequencing using a standard Ml 3 primer. For the establishment of the stable 
RNAi cell lines, HepG2 cells were plated onto 60-mm culture dish for 24 hours to 
reach 90% confluence. 4 ]ig of pSilencer plasmid were transfected into HepG2 cells 
using Lipofectamine 2000 reagent in the presence of 5% FBS. After 24 hours of 
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transfection, one third of the cells were passed to a 100-mm culture dish and 600 
[ig/ml G418 was added on next day. A dish of untransfected control cells was 
performed in parallel. After one week of incubation (when all the untransfected 
control cells has been killed by G418), 1000, 2000 and 3000 transfected cells were 
transferred to a new 100-mm culture dish respectively in G418 free medium. The 
cells were allowed to grow until the cell colonies could be observed under naked 
eyes. Individual clones of cells were trypsinized by 3MM filter paper pre-soaked in 
IX trypsin and passed to 6-well plate. Subsequently cells were passed to 100-mm 
culture dish when confluent and maintained in 300 |Lig/ml G418. Stable cell clones 
were screened by Western blot analysis or RT-PCR and the clone showing the best 
RNAi effect was used in further experiment. 
2.2.2.3 Transient gene transfection 
Cells were seeded on 3 5-mm culture dishes for 24 hours to reach 70-80% 
confluence. For each transfection, 2 |Lig of pCMV6-XL4-H 19 plasmids were mixed 
with 4 jil Lipofectamine 2000 reagent in serum free medium and incubated at room 
temperature for 20 minutes to form stable complexes. The complexes were diluted 
with 5% medium, transferred to the culture dishes and incubated in a 37°C 
humidified 10% CO2 incubator for 24, 48 or 72 hours. 
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2.2.2.4 RNA isolation and RT-PCR 
Total RNA was isolated by lysing cells with Trizol Reagent. RNA was extracted 
by 1/10 volume 1 -bromo-3-chloropropane (BCP) reagent and the supernatant was 
collected after centrifugation at 14000 rpm at 4�C for 15 minutes. Equal volume of 
isopropanol was added to the supernatant. The samples were then shaked vigorously 
and stored at room temperature for 10 minutes to precipitate RNA. RNA pellet was 
collected by centrifugation at 14000 rpm at 4°C for 15 minutes. After drying in air, 
the RNA pellet was dissolved in DEPC-treated water and incubated at 60°C for 10 
minutes. RNA sample was immediately converted to cDNA by reverse transcription 
or stored at -70°C. RNA concentration was calculated by measuring absorbance at 
260 nm. 
For RT-PCR, 2.5 fig of total RNA was used for the synthesis of the first strand 
cDNA. Total RNA was incubated with 0.25 |ig oligo-dT primers and 0.5 mM dNTP 
mix and heated at 70�C for 5 minutes. After heating, RNA was kept on ice for 2 - 3 
minutes. The first strand cDNA was synthesized by M-MLV reverse transcriptase in 
IX first strand RT buffer at 42�C for 60 minutes. The gene of interest was amplified 
by corresponding gene specific primers at concentration of 100 nM. The PGR 
mixture contained IX PGR buffer, 2 mM MgCl2, 200 nM dNTP mix and 1.25 U Taq 
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DNA polymerase. After 20 - 35 cycles of amplification, the PCR product was 
resolved in 1.5 — 2% agarose gel and visualized under UV light. Primer sequences 
were listed in Table 3.3. 
2.2.2.5 MTT drug sensitivity assay 
Cells in 100 |LI1 medium were seeded in 96-well flat bottom plate for 2 days. 100 
\xl of various concentrations of drugs were added to wells and incubated for another 2 
days. After incubation, medium in the well was removed and 50 |li1 of 0.1 mg/ml 
M T T was added for incubation for 3 hours at 3 7 � C . 150 |LI1 D M S O was added to each 
well and incubated at room temperature for 30 minutes with shaking. Absorbance 
was read at 570 run in microplate reader. The sensitivity of the cells to the drugs was 
calculated as the percentage of the absorbance of the cells without drug treatment. 
2.2.2.6 Western blot analysis 
Cells with or without the treatment were washed 3 times with cold PBS 
containing 1 mM sodium ortho-vanadate, scraped and then lysed with Lammeli's 
solution (0.9X PBS, 21 \ig/m\ Aproptinin, 0.5 \ig/m\ Leupeptin, 4.9 mM MgCl?，1 
mM Sodium ortho-vanadate, 1% Triton-X 100, 1 mM PMSF). Protein lysate was 
collected by centrifugation at 14000 rpm at 4�C for 7 minutes and supernatant was 
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taken for protein quantification by BCA Protein Assay Reagents. The remaining 
supernatant was added with equal volume of 2X SDS sample buffer and denatured 
by boiling for 10 minutes. Denatured protein samples (15 - 25 |Lig) were loaded into 8 
- 1 5 % SDS-PAGE minigel and run at 200 V for 50 minutes. Proteins were then 
transferred onto an Immobiline-P membrane soaked with E-blot transfer buffer at 15 
V for 50 minutes. The membrane was blocked with 5% non-fat milk at 4�C overnight 
and then washed with PTB-T (IX PBS with 0.1% Tween 20). The membrane was 
incubated with primary antibody at room temperature for 2 hours and then probed 
with the corresponding secondary antibody conjugated with horseradish peroxidase 
in 1:10000 dilution for an hour. After stringency washes, chemiluminescence signal 




2.3.1 Expression of H19 RNA in different human cancer cell lines 
The expression of HI9 RNA is developmental and tissue specific. It is 
abundantly expressed in placenta and a number of organs during fetal development, 
but silenced in normal adult tissues except skeletal and cardiac muscle. However, 
expression of HI9 was found in certain cancer cell lines. As an initial attempt to 
study the role of HI9 in cancer biology, the expression of HI9 in several cell lines 
were screened by RT-PCR. It was found that HI9 was expressed in three 
hepatocarcinoma lines, HepG2, multi-drug resistant HepG2 (R-HepG2) and Hep3B 
cells, but silenced in other cell lines: Saos2 (human osteosarcoma cells)，MES-SA 
(human uterine epithelial carcinoma cells), A431 (human squamous carcinoma cells) 
and Caco2 (human colonic carcinoma cells) (Figure 2.2). 
2.3.2 R-HepG2 cells over-expressed P-glycoprotein and HI 9 RNA 
The R-HepG2 cells were derived from the HepG2 cells by a step-wise treatment 
of cells with increasing concentrations of doxorubicin (DOX). R-HepG2 displayed 
multi-drug resistance to different drugs such as DOX and vincristine (VCR). By 
MTT cell viability assay, R-HepG2 cells are generally more resistant to DOX than 
the parent HepG2 cells (Figure 2.3A). The increased drug resistance is thought to be 
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Figure 2.2 Expression of H19 RNA in different human cancer cell lines. Cells 
were lyzed with Trizol reagent and total RNA was precipitated for RT-PCR 
amplification with H19 specific primers. PCR products were resolved in 1.5% 
agarose gel. The level P-actin was co-amplified as an internal control. HepG2: 
human hepatocellular carcinoma cell; R-HepG2: DOX-resistant HepG2 subline; 
Saos2:human osteosarcoma cell; MES-SA: human uterine epithelial cell, A431: 
human squamous carcinoma cells; Caco2: human colonic carcinoma cells; M: 100 
bp DNA marker. Primers sequences were listed in Table 3.3. 
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due to the upregulation of P-glycoprotein, the product of MDRl gene. P-glycoprotein 
is a membrane protein that pumps a variety of drugs into the extracellular medium in 
an ATP-dependent manner. Therefore, upregulation of MDRl expression reduces 
intracellular accumulation of cytotoxic drugs. In R-HpeG2 cells, both P-glycoprotein 
and HI9 RNA were found to be upregulated as compared to the parent HepG2 cells 
(Figure 2.3B). The relationship between MDRl and HI9 is unknown from the 
literature. The overexpression of MDRl and HI9 in R-HepG2 cells suggested that 
these two genes may correlate and play a role in drug resistance, other than the tumor 
suppression role and oncogenic property in cells. 
2.3.3 Development of H19-silenced cell lines in HepG2 cells by RNA interference 
RNA interference (RNAi) by small interfering RNA (siRNA) or short hairpin 
RNA (shRNA) has become a popular method in recent years as a tool for 
post-transcriptional gene silencing in cell lines or even in animals. Gene knockdown 
by RNAi has gained advantages in efficiency, specificity, convenience and 
consistency. In this study, the siRNA/shRNA target sequence of HI9 was designed 
by Ambion's "siRNA Target Finder". Subsequently, siRNA duplex was prepared by 
in vitro transcription according to Ambion's “Silencer siRNA construction kit". The 
efficiency of the siRNA was determined by transient transfection of 100 nM siRNA 
26 
A ' � � 




20 — H e p G 2 
— R - H e p G 2 *p<0.05 
0 ‘ ‘ ‘ 
0 0.1 0.2 0.3 0.4 
DOX Cone. (|Lig/ml) 
O D HepG2 R-HepG2 
170 kDa j ^ ^ ^ M M t e P - g l y c o p r o t e i n 
imimiii^ii RNA 
Figure 2.3 Expression of P-glycoprotein and H19 RNA in HepG2 and R-HepG2 
cells. (A) DOX sensitivity of HepG2 and R-HepG2 by MTT assay. Cells were 
seeded in 96 well-plate for 2 days and then treated with DOX for another 2 days. 
Survival cells were assessed by MTT assay. Mean 土 S.E.M. from 4 independent 
experiments. (B) The protein level of P-glycoprotein by Western blot analysis and 
RNA level of HI9 by RT-PCR. For Western blot analysis, 30|Lig of protein was 
resolved in denaturing 8% SDS-PAGE and immunoblotted with polyclonal anti-P-
glycoprotein antibody. For RT-PCR reaction, cells were lyzed with Trizol reagent 
and total RNA was precipitated for RT-PCR amplification with HI9 specific primers. 
The PCR products were resolved in 1.5% agarose gel. Primers sequences were listed 
in Table 3.3. 27 
for 24，48 and 72 hours. Afterwards, a DNA cassette expressing shRNA against the 
tested siRNA-sense sequence was cloned to an in vivo expressing vector (pSilencer 
2.1-U6, Ambion) driven by human U6 promoter (Figure 2.4A). Another DNA 
cassette expressing shRNA against green fluorescent protein (GFP) was cloned in 
parallel as a non-specific RNAi control. DNA sequencing was performed to confirm 
the correct ligation of DNA insert into the vector. For development of H19-silenced 
stable cell lines, HepG2 cells were transfected with shRNA-expressing pSilencer 
plasmid for 24 hours and then selected by 600 \ig/m\ G418 (Figure 2.4B). Individual 
clones of stable transfectants were picked and the RNAi effect in these clones was 
assessed by detecting the relative HI9 expression level. Four stable HI9 RNAi 
clones (HI - H4) were successfully developed. Among these clones, H2 was found to 
be most effective in HI9 gene silencing (Figure 2.4C). This clone was used in the 
subsequent study. 
2.3.4 Altered drug sensitivity in H19-silenced cells 
The finding that HI9 is overexpressed in multi-drug resistant HepG2 cells might 
suggest a regulatory role of this non-coding RNA in drug resistance. To test this 
hypothesis, MTT cell viability assay was used to study the change in drug sensitivity 
in H19-silenced cells, clone 2 (H2). Three common chemotherapy drugs, 
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Figure 2.4 Development of H19-silenced HepG2 cells by RNA interference. (A) 
The DNA cassette encoding a hairpin RNA that specifically targeted HI9 RNA was 
ligated to the pSilencer 2.1-U6 plasmid and the sequence was verified by DNA 
sequencing. (B) Schematic diagram showing the development stable H19-RNAi 
sublines in HepG2 cells. Cells were seeded on culture dish for 24 h before 
transfection. After 24 h gene transfection, one-tenth of the cells were passed to a 
new dish followed by the addition of 600 jag/ml G418. Individual clones were 
selected and kept in 300 jag/ml G418 medium. (C) The levels of H19 RNA in four 
H19-RNAi sublines (H1-H4) and their parent HepG2 cells (G) were assessed by 
RT-PCR. p-actin was used as an internal control. M: 100 bp DNA marker. Primers 
sequences were listed in Table 3.3. 
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doxorubicin (DOX), paclitaxel (Taxol) and 5-flurouracil (5-FU) were tested. Results 
from MTT assay revealed that HI9 knockdown increased Taxol and DOX sensitivity 
as compared to the parent or RNAi control cells (Figure 2.5). Alteration of drug 
sensitivity by Taxol was more apparent than DOX. However, HI9 knockdown did 
not show any effect upon 5-FU treatment, perhaps due to different drug action. 
2.3.5 Expression of P-glycoprotein in H19-silenced cells 
To test whether HI9 plays a role in drug resistance through P-glycoprotein, the 
expression level of P-glycoprotein in the four stable HI9 RNAi clones was 
determined by Western blot analysis. It was found the P-glycoprotein level was 
generally declined in these four clones. Since the efficiency of HI9 knockdown in 
the individual clones was different (Figure 2.4C), the expression level of 
P-glycoprotein in the corresponding clones also varied (Figure 2.6). Among the four 
clones, H2 was found to be most significant in HI9 silencing. Correspondingly, the 
P-glycoprotein in H2 was down-regulated most significantly. As the HI9 RNA level 
was correlated to P-glycoprotein level, it is therefore suggested that HI9 might 
regulate P-glycoprotein directly or indirectly. 
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Figure 2.5 Effect of H19 knockdown on Taxol, DOX and 5-flurouracil 
sensitivity. Cells were plated in 96-well plates for 2 days followed by treatment of 
various concentrations of drugs for another 2 days. Survival cells were assessed by 
MTT dye reduction. Percentage survival of cells was calculated as the proportion of 
viable cells with drug treatment to those cells without drug treatment. G: HepG2 
parent cells; C: RNAi control cells; H19i (H2): H19 RNAi cells (clone 2). Mean 土 
S.E.M. from 3 independent experiments. 
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Figure 2.6 Analysis of P-glycoprotein expression level in H19-RNAi sublines by 
Western blot analysis. P-glycoprotein level was determined by Western blot 
analysis. Basal proteins of the four H19-RNAi sublines were lysed and resolved in 
SDS-PAGE gel. Proteins were transferred to membranes and probed with primary 
polyclonal anti-P-glycoprotein antibody and its corresponding secondary antibody. 
(3-actin was used as an internal control. G: HepG2 parent cell; H1-H4: stable H19-
RNAi sublines. Primers sequences were listed in Table 3.3. 
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2.3.6 Overexpression of H19 RNA in HepG2 cells 
Results from RNAi experiment indicated that HI9 RNA positively regulated 
MDRl expression. To further confirm this regulatory relationship, HI9 was 
overexpressed in HepG2 cells. The mammalian expression vector pCMV6-XL4 
carrying a 2.2kb HI9 cDNA was obtained by PGR screening from a human placenta 
cDNA library (refer to Materials and Methods in Chapter 4). When HepG2 cells were 
transfected with H19-expressing plasmids, the HI9 RNA level was boosted rapidly 
after 24 hours gene transfection, and leveled off up to 72 hours, as revealed by 
RT-PCR. The MDRl mRNA levels in the H19-transfected cells were also measured 
by RT-PCR. Results from Figure 2.7 show that the level of MDRl mRNA also 
increased significantly at 72 hours after transfection. Overexpression of HI9 RNA in 
HepG2 cells increased MDRl expression, further supporting the regulatory role of 
H19RNAon MDRl. 
2.3.7 Induction of H19 RNA and MDRl in HepG2 cells 
Since HI9 RNA inhibition resulted in decrease of P-glycoprotein, the 
expression of these two genes might be closely associated. It is known that when 
cells are exposed to drugs such as DOX, the MDRl expression was upregulated. In 
this study, the effect of gamma radiation on the expression of MDRl/P-glycoprotein 
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Figure 2.7 The effect of HI9 overexpression on MDRl mRNA expression in 
HepG2 cells. HepG2 cells were seeded on 35-mm culture dishes for 24 hours and 
then transfected with 2 |Lig pCMV6-XL4 plasmids containing a 2.2 kb HI9 cDNA 
by using Lipofectamine 2000 transfection reagent. After 24, 48 and 72 hours 
transfection, cells were lysed with Trizol reagent and total RNA was extracted and 
precipitated. RNA was converted cDNA by reverse transcription. The relative 
mRNA expression levels were measured by PCR using HI9, MDRl and p-actin 
specific primers. Primers sequences were listed in Table 3.3. M: 100 bp DNA 
marker; Ctr: untransfected control. 
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and HI9 RNA was tested. When HepG2 cells were irradiated with 10 Gy gamma ray, 
the HI9 RNA expression was induced, most significantly at 24 hours after irradiation. 
Meanwhile, the P-glycoprotein was elevated (Figure 2.8). Although the underlying 
mechanism of radiation-induced expression of HI9 and MDR 1 /P-glycoprotein is 
unknown, the co-induction of these two genes suggests they are closely related. 
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Figure 2.8 Co-induction of HI9 RNA and P-glycoprotein by gamma radiation. 
HepG2 cells were seeded on 60-mm culture dishes for 2 days and then irradiated 
with 10 Gy gamma ray. Cells were lysed to extract total RNA and total proteins at 
indicated time. The relative HI9 RNA level was determined by semi-quantitative 
RT-PCR while the P-glycoprotein level was determined by Western blot analysis 
using polyclonal anti-P-glycoprotein antibodies. Primers sequences were listed in 
Table 3.3. Ctr: control cells without gamma irradiation. 
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2.4 Discussion 
2.4.1 H19 regulation of MDRl associated drug resistance 
In chemotherapy, prolonged exposure of cancer cells to anti-cancer drugs like 
DOX may develop multi-drug resistance phenotype. This is one of the obstacles in 
clinical cancer treatment. The cause of MDR phenotype is multiplex. It can be due to 
the increased drug efflux by P-glycoprotein and/or multidrug resistance-associated 
protein (MRP) (Bradley et al. 1988; Loe et al. 1996). Increased expression of drug 
detoxification enzymes like glutathione-S-transferase (GST) or drug metabolism 
enzymes like dihydrofolate reductase will also confer drug resistance (Misra et al. 
1961; Tew 1994). Some of the MDR cells increase their expression of DNA damage 
repair proteins such as DNA-PK and BRCA-1 (Husain et al. 1998; Shen et al. 1998). 
Last but not the least, upregulation of anti-apoptotic genes such as Bcl-2 and Bax 
will also confer drug resistance by reducing drug-induced apoptosis (Nuessler et al. 
1999; Reed et al. 1994). 
In R-HepG2 cells, MDR phenomenon is known to be conferred by the 
overexpression of MDRl/ P-glycoprotein. P-glycoprotein is a membrane protein that 
pumps a variety of drugs into the extracellular medium in an ATP-dependent manner. 
Therefore, upregulation of MDRl expression reduces intracellular accumulation of 
cytotoxic drugs (Bosch & Croop 1996). The regulation of MDRl is also a complex 
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process that might involve MDRl mRNA stability, P-glycoprotein turnover, protein 
trafficking, or transcriptional activation of the gene. Transcription of the MDRl gene 
can be enhanced by the exposure to chemotherapeutic drugs, UV light or heat shock. 
Transcription factors like Spl or AP-1 may bind to the MDRl promoter and hence 
affect its transcription. DNA methylation in the MDRl promoter region is also a 
critical factor that controls transcription (Labialle et al. 2002; Yague et al. 2003). 
In this study, a regulatory function of HI9 non-coding RNA in MDRl 
expression was proposed. The hypothesis is based on the fact that HI9 RNA is 
overexpressed in R-HepG2 cells. To test this hypothesis, H19-silenced HepG2 
sublines were developed by RNAi. RNAi is a powerful technique for 
post-transcriptional gene silencing. It has been widely employed in functional studies 
of genetics. RNAi-based gene knockdown is more convenient than conventional 
gene knockout by homologous recombination method, especially in cell lines. There 
were four HI9 RNAi clones successfully selected. Among these, the expresson of 
HI9 was almost completely silenced in the second clone (named H2). In the 
subsequent study, results from MTT assay showed an altered drug sensitivity in H2 
cells. Western blot analysis revealed a reduced level of P-glycoprotein. It was 
therefore suggested that H19 confer drug resistance through regulation of 
MDRl/P-glycoprotein expression. 
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2.4.2 The puzzle of riboregulation in drug resistance 
The term "riboregulation" refers to those gene regulation mediated by RNA 
molecules. HI9 has long been described as a riboregulator, although the function(s) 
of HI9 is yet not so clear. In many aspects, HI9 RNA is similar to those 
protein-coding RNAs in that it is transcribed by RNA polymerase II in the nucleus, 
and then processed to mature RNA by capping, splicing, polyadenylation and 
transportation to the cytoplasm. Although the cytoplasmic HI9 RNA had been shown 
to associate with polysomes, no translation product was detected (Li et al. 1998). If 
the assumption that HI9 acts as a riboregulator is correct, one should expect it might 
associate with some factors (protein, nucleic acid or other forms of biomolecules) to 
form a complex that mediate the process of regulation. Riboregulation using this 
mechanism includes siRNA-mediated mRNA degradation by RISC (RNA-induced 
silencing complex) and miRNA-mediated mRNA inhibition by miRNP 
(microRNA-protein complex) (Okamura et al. 2004). In addition, nuclear snRNAs 
also complex with RNA-binding proteins to form snRNPs (small nuclear 
ribonucleoprotein particles) complexes that assist pre-mRNA splicing (Seraphin & 
Rosbash 1989). Interaction of H19 RNA with other RNA transcripts is possibly not 
the underlying mechanism, since there is no sequence homology between HI9 and 
other transcripts. However, the possibility of forming a secondary functional 
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structure and the subsequent interaction with other proteins or nucleic acids cannot 
be excluded. This kind of RNA molecules is sometimes called "aptamer" that can 
bind specifically to other molecules (Nimjee et al. 2005). 
Given that HI9 exists as a riboregulator, the mechanism of HI9 regulation in 
drug resistance through MDRl is unknown. By similar experiments, Tsang et al used 
antisense oligos to inhibit HI9 expression in R-HepG2 cells. It was shown that the 
reduction of MDRl expression was arisen with the increased DNA methylation in 
the MDRl promoter region (unpublished data). How HI9 affects the methylation of 
MDRl promoter is still a puzzle. It is logically to deduce that HI9 is able to change 
the epigenetic status of MDRl gene, other than Igf2. Whether HI9 RNA regulates 
MDRl expression in a manner similar to that for Igf2 might help us to have a better 
understanding on this novel type of riboregulation. 
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CHAPTER THREE 
The Roles of PTB and IMPl in H19-related MDRl 




3.1.1 H19 RNA binding proteins 
Although HI9 RNA has been identified for more than two decades, its 
interacting partners were almost unknown. This makes the underlying molecular 
mechanism unclear. However, more and more evidences show that this RNA has 
regulatory functions in different aspects such as fetal development, tumor 
suppression, carcinogenesis and, in this study, drug resistance. It would therefore be 
very interesting to investigate the interaction of this novel type of riboregulation. 
In an attempt to identify the RNA binding proteins that bind IGF2 mRNA leader 
3 non-coding region, Nielsen et al accidentally found that one of the IGF2 mRNA 
binding proteins, called IMPl (IGF2 mRNA binding protein 1)，can also bind to HI9 
in vitro. On the other hand, another RNA-binding protein called polypyrimidine 
tract-binding protein (PTBPl or PTB) can also bind to HI9 RNA in a competitive 
manner with IMPl (Runge et al. 2000). 
PTB (also called hnRNP I) is a nuclear RNA binding protein found in the 
perinucleolar compartment (PNC), which is a structure localized at the periphery of 
the nucleolus (Wang et al. 2003). PTB binds with a variety of RNA molecules 
including pre-mRNA, mature mRNA and some viral RNA (Grossman et al. 1998; 
Huang et al. 1997). A detailed review of PTB will be covered in Chapter 5. 
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IMPl contains two RNA recognition motifs (RRM) and four heterogeneous 
nuclear ribonucleoprotein K homology (KH) domains. It can associate specifically 
with the 5' UTR of IGF2 mRNA that is called leader 3 mRNA. Binding of IMPl to 
leader 3 mRNA represses the translation of the reporter mRNA (Nielsen et al. 1999). 
The close relationship between HI9 and IGF2 is implicated by their reciprocal 
imprinting characteristics and their similar spatiotemporal expression pattern (Mutter 
et al. 1993). Furthermore, the ability of IMPl to bind both H19 and IGF2 mRNA 
might imply a higher level of complexity in the network of RNA-protein interactions. 
IMPl shares a common binding property with PTB in binding IGF2 leader 3 mRNA 
and HI9 RNA (Runge et al. 2000). However, PTB has been found to bind to a 
variety of target RNA molecules in the pyrimidine-rich region (the role of PTB in 
post-transcriptional gene regulation will be discussed in Chapter 5), whilst IMPl is 
known to interact with a limited number of RNA molecules. 
Remarkably, the role of IMPl is more evident in cancer biology. IMPl was 
originally identified as CRD-BP (c-myc mRNA coding region determinant-binding 
protein). CRD-BP/IMPl can protect c-myc mRNA degradation in a cell-free mRNA 
decay system (Bernstein et al. 1992). It is suggested that this protein functions to 
maintain c-Myc expression which is required for promoting cell proliferation. 
CRD-BP/IMPl is also known as an oncofetal protein. It is highly expressed in fetal 
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and neonatal mammals and also in some tumors (Doyle et al. 2000; loannidis et al. 
2001; Leeds et al. 1997; Ross et al. 2001). Its expression is declined or absent in 
normal adult tissues (Nielsen et al. 1999). CRD-BP expression in mammary 
epithelial cells of adult transgenic mice induced mammary tumors in the animals 
(Tessier et al. 2004). The oncofetal property of IMPl is very similar to HI9， 
suggesting that this RNA-binding protein may interact with HI9 RNA to perform 
some specific functions. 
Given the fact that IMPl shows similarity with HI9 in oncogenesis and PTB is 
able to compete the binding with IMPl, it is therefore hypothesized that these two 
RNA-binding proteins might mediate the regulatory function of HI9 in drug 
resistance. In this study, RNAi was employed to stably knockdown the expression of 
PTB or IMPl in HepG2 cells. The effect of protein depletion of PTB or IMPl on the 
expressions of the MDRl/HI 9 was examined. The inter-relationship between 
PTB/IMPl and H19/MDR1 provides additional clue to the understanding of the 
underlying mechanism of riboregulation. 
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3.2 Materials and methods 
3.2.1 Materials 
Chemicals/Reagents Company/Supplier 
Doxorubicin (DOX) Sigma 
Power SYBR green PCR master mix Applied Biosystems 
Taxol / paclitaxel Sigma 
TNF-a Calbiochem 
Verapamil Sigma 
For other chemicals or reagents used in cell culture, plasmid construction, stable 
cell transfection, RNA isolation, RT-PCR, MTT drug sensitivity assay and Western 
blot analysis, please refer to Chapter 2.2.1. 
Antibodies Company/Supplier 
anti-(3-actin antibody Sigma 
anti-CRDBP/IMPl antibody Santa Cruz 
anti-Goat IgG HRP-conjugate Zymed 
anti-MDR 1 /P-glycoprotein antibody Oncogene 
anti-Mouse IgG HRP-conjugate Zymed 
anti-PTB antibody Zymed 
anti-Rabbit IgG HRP-conjugate Zymed 
Culture wares Company/Supplier 
96-well flat bottom culture plate Nunc 
3 5-mm culture dish TPP 
60-mm culture dish TPP 
100-mm culture dish Iwaki 
Instruments/Equipments Company/Supplier 
3-MM filter paper Whatman 
FACSort flow cytometer Becton Dickinson 
Fast Real Time PCR System 7500 Applied Biosystems 
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Film cassette Kodak 
Gammacell 3000 Elan Irradiator MDS Nordion 
GeneAmp PCR system 9700 Applied Biosystems 
Microplate reader Molecular Device 
Mini-Protean II electrophoresis apparatus Bio-Rad 
Trans-Blot SD semi-transfer cell Bio-Rad 
UV transilluminator UVP 
X-ray film Fuji 
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3.2.2 Methods 
3.2.2.1 Cell culture 
Refer to Chapter 2.2.2 for cell culture conditions. 
3.2.2.2 Plasmid construction and stable cell transfection 
The shRNA target sequences for PTB and IMPl mRNA were listed in Table 3.2. 
The target sequence for PTB was adopted from Zhang et al. (Zhang et al. 2004) 
Refer to Chapter 2.2.2 for methods in plasmid construction and stable cell 
transfection. 
3.2.2.3 RNA extraction and RT-PCR 
Refer to Chapter 2.2.2 for methods in RNA extraction and RT-PCR. Primer 
sequences were listed in Table 3.3. 
3.2.2.4 MTT drug sensitivity assay 
Refer to Chapter 2.2.2 for methods in MTT drug sensitivity assay. 
3.2.2.5 Western blot analysis 
Refer to Chapter 2.2.2 for methods in Western blot analysis. 
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3.2.2.6 Real-time PCR analysis of gene expression 
Real-time PCR was performed by using SYBR green PCR master mix. In each 
20 |Lil PCR reaction, 1 \i\ of each primer (5 i l i M ) was mixed with 10 J^ l SYBR green 
master mix and 1 ill cDNA template. PCR reaction was performed in Fast Real Time 
PCR 7500 (Applied Biosystem) using standard mode, and analyzed in 7500 Fast 
System Software. Relative gene expression was calculated by the method 
(Livak, Schmittgen 2001). Primer sequences used in real-time PCR were listed in 
Table 3.3. 
3.2.2.7 DOX efflux assay 
For each analysis, 3.75 x 10^ cells were seeded on 35-mm dish overnight. Cells 
were exposed to 5 jig/ml DOX for one hour at 37�C to allow rapid influx of drug. 
After that, the medium was replaced with drug-free phenol-red free medium and the 
cells were allowed to incubate for 3 hours. In another control experiment to 
demonstrate the effect of P-glycoprotein in drug efflux, cells were pre-incubated with 
30 |jM verapamil for one hour before exposure to drug. DOX accumulation in cells 
was assessed by the emitted fluorescent intensity at 570 nm (FL2-H) on a FACSort 
flow cytometer. Data were analyzed by software WinMDI 2.8 and the peak channel 
value of each sample was collected. Percentage of DOX accumulation was calculated 
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as the ratio of normalized peak channel value of cells incubated in 3-hour drug-free 
medium after 1-hour DOX exposure to that of cells incubated in 1-hour DOX. 
50 
3.3 Results 
3.3.1 PTB knockdown increased P-glycoprotein expression 
In this study, PTB was knockdown by RNAi by employing a similar strategy as 
in the knockdown of HI 9 in HepG2 cells. Stable RNAi cells were developed. One of 
the clones showed the best PTB silencing effect was subsequently named as GPi. 
Western blot analysis indicated that, with PTB being depleted, the level of 
P-glycoprotein was elevated to about 2 folds (Figure 3.1 A). P-glycoprotein is a 
membrane protein that can pump cytotoxic drugs like DOX to the extracellular space. 
Thus, overexpression of P-glycoprotein infers MDR phenomenon. To test whether 
the elevated level of P-glycoprotein as revealed by Western blot analysis is functional, 
the drug efflux ability of cells was assayed by flow cytometry. The cells were treated 
with high concentration of DOX (5 |ig/ml) for 1 hour followed by 3 hours of drug 
free medium and the intracellular level of DOX was assessed in terms of fluorescent 
intensity with excitation at 488 nm and emission at 570 nm on a FACSort flow 
cytometer. Data from the flow cytometric analysis showed a reduced accumulation of 
DOX in GPi cells, as compared to that in the HepG2 parent or RNAi control cells 
(Figure 3.1 B). This indicated that the increased P-glycoprotein was functional in 
pumping DOX out of cells. 
Since the alteration of MDRl/P-glycoprotein could be H19-related, as revealed 
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Figure 3.1 Effect of PTB knockdown on the expressions of P-glycoprotein and 
HI9 RNA in HepG2 cells. (A) HepG2 cells were transfected with shRNA-
expressing plasmids targeting either PTB (GPi) or GFP (C). PTB and P-
glycoprotein expression levels were revealed by Western blot analysis. The level of 
P-actin was shown as internal control. (B) The effect of PTB knockdown in HepG2 
cells (GPi) on DOX efflux was revealed by flow cytometry. Cells were treated with 
5 [ig/m\ DOX for 1 hour at 37°C and then incubated in drug free medium for another 
3 hours. Cells were washed and resuspended in cold PBS. DOX accumulation in 
cells was assessed by the emitted fluorescent intensity at 570 nm (FL2-H) on a 
FACSort flow cytometer. Data were analyzed by software WinMDI 2.8 and the 
peak channel value of each sample was collected. Percentage DOX accumulation 
was calculated as the ratio of normalized peak channel value of cells incubated in 
drug-free medium for 3 hours to that of the cells immediately after 1 -hour DOX 
exposure. (C) The effect of PTB knockdown on the expression of HI9 RNA. Cells 
were lysed with Trizol reagent and total RNA was extracted. The level of HI9 
RNA was determined by semi-quantitative RT-PCR, with p-actin was co-amplified 
as an internal control. Where indicated, G: HepG2 parent cells; C: vector control 
cells; GPi: PTB knockdown cells; M: 100 bp DNA marker. Primers sequences were 
listed in Table 3.3. 
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in Chapter 2, we further address the possibility of PTB in regulating 
MDRl/P-glycoprotein through H19. By RT-PCR, the level of H19 RNA in 
PTB-inhibited cells was significantly decreased (Figure 3.1 C). The result is 
contradictory to the previous finding that downregulation of HI 9 expression resulted 
in reduced MDR1 /P-glycoprotein level. Therefore, PTB is thought not to mediate 
HI9 effect on MDRl expression. In order to study the role of HI9 interacting 
proteins in modulating MDRl/P-glycoprotein expression, another HI 9 binding 
protein, IMPl, was studied. 
3.3.2 IMPl knockdown decreased MDRl/P-glycoprotein expression 
IMPl has previously been shown to be able to bind to HI9 RNA in competition 
with PTB by using in vitro RNA-binding assay (Runge et al. 2000). The possibility 
of IMPl in modulating H19-related MDR 1 /P-glycoprotein expression was tested. 
Using similar methodology, IMPl was knocked down specifically by shRNA. Three 
stable HepG2 clones transfected with IMPl specific shRNA were developed. These 
three clones inhibited IMPl expression to different extent (Figure 3.2 A). Similar to 
the observation in HI9 RNAi, knockdown of IMPl resulted in a decreased 
expression of MDRl mRNA by RT-PCR (Figure 3.2 A). The relationship between 
IMPl and MDRl was further analyzed by quantitative real-time PCR (Figure 3.2 B). 
54 





















o  —• 
1  ？8  -誠  ISM
Pl 
•观  ！讀  •  MDRl
 
薩。
4  —  一睡  pl^ 
lUil
iiii 






Figure 3.2 Effect of IMPl knockdown on MDRl expression in HepG2 cells. 
HepG2 cells were transfected with shRNA-expressing plasmid targeting human 
IMPl. Stable individual clones (II — 13) were selected in medium containing 600 
l^g/ml G418. Total RNA was extracted and converted to cDNA by reverse 
transcriptase. The relative mRNA expression levels of IMPl and MDRl in IMPl 
knockdown cells were measured by semi-quantitative RT-PCR (A) and quantitative 
real-time PCR (B). Real-time PCR was performed by using Power SYBR Green 
Master Mix and the relative mRNA expression levels of IMPl and MDRl were 
normalized by p-actin. Data represent the mean value of 2 independent experiments. 
Primers sequences were listed in Table 3.3. 
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In all the stable IMPl knockdown clones developed, the MDRl mRNA level was 
reduced to half of the parent cells. The translation product of MDRl, P-glycoprotein, 
was also analyzed by Western blotting (Figure 3.3 A). Similar result was obtained. To 
further confirm the downregulation of MDRl/P-glycoprotein in IMPl knockdown 
cells, DOX efflux assay was performed. Results from flow cytometry showed that 
two of the IMPl knockdown clones (12, 13) displayed an increase in intracellular 
DOX accumulation. To test whether the increased DOX accumulation was due to the 
reduced drug efflux through P-glycoprotein pump, verapamil was added to the cells 
to block the P-glycoprotein channel. As a result, addition of verapamil significantly 
increased intracellular DOX accumulation in HepG2 parent cells (which showed 
higher P-glycoprotein level than IMPl knockdown cells), but the effect in IMPl 
knockdown cells (clone 12, 13) was less obvious (Figure 3.3B). This suggested that 
the reduced expression of P-glycoprotein in IMPl knockdown cells was functional. 
The effect of IMPl knockdown on HI9 expression was also investigated. Using 
semi-quantitative RT-PCR, the HI9 RNA level in IMPl knockdown cells was 
increased (Figure 3.4 A). The change of HI 9 RNA in these cells was more obvious as 
revealed by quantitative real-time PCR (Figure 3.4 B). All the clones showed 6 to 7 
folds of increase. The effect of IMPl knockdown on HI9 level was opposite to that 
of PTB. Interestingly, opposite effect of IMPl/PTB knockdown on 
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Figure 3.3 Analysis of P-glycoprotein expression and DOX efflux in IMPl 
knockdown cells. (A) Expression of IMPl and P-glycoprotein was analyzed by 
Western blot analysis. Cells were lysed and total proteins were resolved in SDS-
PAGE, transferred to nitrocellulose membrane and probed with anti-P-glycoprotein 
and anti-CRD-BP antibodies. (B) DOX efflux in IMPl knockdown cells was 
analyzed by flow cytometry. Cells were exposed to 5 fj,g/ml DOX in 37�C for 1 
hour and then incubated in drug free medium for another 3 hours. In another set of 
experiment, cell were pre-incubated with 30 |LIM verapamil for 1 hour prior to DOX 
treatment. Cells were washed and resuspended in cold PBS. DOX accumulation in 
cells was assessed by the emitted fluorescent intensity at 570 nm (FL2-H) on a 
FACSort flow cytometer. Data were analyzed by software WinMDI 2.8 and the 
peak channel value of each sample was collected. Percentage DOX accumulation 
was calculated as the ratio of normalized peak channel value of cells incubated in 
drug-free medium for 3 hours to that of cells immediately after 1-hour DOX 
exposure. Where indicated, G is HepG2 parent cells, II, 12 and 13 are the IMPl 
knockdown clones of HepG2 cells. 
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Figure 3.4 Effect of IMPl knockdown on H19 expression. Total RNA of IMPl-
knockdown cells or HepG2 parent cells was extracted by Trizol reagent and 
converted to cDNA by reverse transcriptase. (A) The level of HI9 RNA was 
determined by semi-quantitative RT-PCR with p-actin as internal control. (B) The 
level of IMPl mRNA and HI9 RNA was quantified by real-time PCR, as described 
in figure 3.2 (B). Data represent the mean value of 2 independent experiments. 
Primers sequences were listed in Table 3.3. 
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MDR 1 /P-glycoprotein expression was also observed. The relationship between 
IMP 1/PTB and H19/MDR1 was summarized in Table 3.1. 
3.3.3 Altered drug sensitivity in IMPl-knockdown cells 
Since IMPl showed a positive effect on the MDRl expression, the drug 
sensitivities of IMPl knockdown cells were investigated, based on the knowledge 
that MDRl affects different drug sensitivity. One of the IMPl knockdown clones, 13, 
was used for drug screening. It was found that 13 was more sensitive to DOX than 
the parent or RNAi control cells (Figure 3.5). This might be related to the 
downregulation of MDRl/P-glycoprotein in 13 cells, as DOX is one of the substrates 
for P-glycoprotein. 13 cells were also more sensitive to TNF-a, despite the 
insensitive response of HepG2 cells to this cytokine (Figure 3.5). While TNF-a is 
known to kill cells through a signaling pathway by activation of JNK and caspase 
cascade (Malagarie-Cazenave et al. 2002), the effect of IMPl on JNK or apoptosis 
pathway has not been investigated in this study nor reported in literature. The 
response to cytotoxic drug like Taxol, which inhibits depolymerization of 
microtubules and causes cell cycle arrest, and gamma radiation, which is a DNA 
damaging agent, appeared to be independent of IMPl as the cells demonstrated 
similar responses to these two agents. 
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Figure 3.5 Effect of IMPl knockdown on DOX, Taxol, y-radiation and TNF-a 
sensitivity. Cells were plated in 96-well plates for 2 days followed by treatment of 
various concentrations of drugs for another 2 days (DOX, Taxol, y-radiation) or 3 
days (TNP-a). Survival cells were assessed by MTT dye reduction. Percentage 
survival of cells was calculated as the proportion of viable cells with drug treatment 
to those cells without drug treatment. G: HepG2 parent cells; C: RNAi control cells; 
13: IMPl RNAi cells (clone 3). Mean 土 S.E.M. from 3 independent experiments. 
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Table 3.1 Inter-relationship of H19, PTB, IMPl and MDRl expression in 
HepG2 cells. The effect ofRNAi-based knockdown of HI9，PTB and IMPl on the 
expression of HI9 and MDRl was summarized. Where indicated, “ f ” denotes 
increase expression while “ I，’ denotes decrease expression. 
_ . m R N A A c c e s s i o n T a r g e t s e q u e n c e . ‘• . 口 1 p o s i s t i o n n u m b e r 
H 1 9 5 ' - C A T C A A A G A C A C C A T C G G A - 3 ' 1724-1742 NR_002196 
P T B 5 ' - A G C G G G G A T C T G A C G A G C T - 3 ' 110-128 BC023219 
I M P 1 5 ' - C C T G G C T G C T G T A G G T C T T - 3 ' 690-708 DQ227344 
G F P 5 ' - G G T T A T G T A C A G G A A C G C A - 3 ' 271-289 X83960 
Table 3.2 The siRNA/shRNA target sequences used in the study. The 
siRNA/shRNA target sequences for HI9 and IMPl were designed by Ambion's 
"siRNA target finder". Efficiency of each sequence was tested with in vitro 
synthesized siRNA by Ambion's “siRNA construction kit". DNA cassettes for the 
expression of each shRNA were cloned into a mammalian expression vector 
pSilencer 2.1-U6. The shRNA target sequence for GFP was provided by Ambion 
while that of PTB was adapted from literature (Zhang et al, 2004). Primer oligos 
were chemically synthesized by Tech Dragon Inc.. 
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S e m i - q u a n t i t a t i v e R T - P C R Q u a n t i t a t i v e r e a l - t i m e P C R 
Forward: Forward: 
5 ' -TAC A A C C A C T G C A C T 5 ’ -AGC G G G TCT G T T T C T T T A 
A C C TG-3 ’ C T T CCT-3， 
U < 1 Q 
Reverse: Reverse: 
5 ' -TGG A A T G C T T G A A G G 5 ' -GGT A G C A C C A T T T C T T T C 
C T G CT-3 ' A T G T T G T-3， 
Forward: Forward: 
5，-CCC A T C A T T G C A A T A 5，-GCA G C T G G A A G A C A A 
G C A GG-3， A T A C A C AAA-3 ' 
M D R 1 
Reverse: Reverse: 
5 ' -GTT C A A A C T T C T GCT 5 ' -CCC C A A C A T C G T GCA 
C C T GA-3’ C A T C-3 ' 
Forward: Forward: 
5 ' -AGG A A G GAG A A C G C A 5，-AGG A A G G A G A A C G C A 
G G T G-3 ' G G T G-3 ' 
• M P 1 
Reverse: Reverse: 5，-GCA A C G A G G A G A T G G 5 ' -GCA A C G A G G A G A T G G 
T G A TT-3， T G A TT-3， 
Forward: Forward: 
5 ’ -GCG G G A A A T CGT GCG 5 ’ -ACA C C C C A G CCA T G T 
• T G A CAT T-3， A C G TT-3 ' 
p - a c t i n Reverse: Reverse: 
5 ' -GAT G G A GTT GAA G G T 5 ' -TCA C C G G A G T C C A T C 
A G T T T C GTG-3 ' A C G AT-3， 
Table 3.3 Primers used in semi-quantitative RT-PCR and quantitative real-
time PCR. Primers for semi-quantitative RT-PCR were designed by software 
"Primer3" (available online: http:"frodo.wi.mit.edu/cgi-bin/primer3/primer3一www. 
cgi). Primers for quantitative real-time PCR were designed by software "Primer 
Express 3.0 ” according to the vendor's suggested criteria. Primer oligos were 
chemically synthesized by Tech Dragon Inc.. 
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3.4 Discussion 
3.4.1 Antagonistic effect of PTB and IMPl on H19/MDR1 expressions 
In this chapter, the roles of two putative HI9 RNA binding proteins, PTB and 
IMPl, were investigated by RNAi-based knockdown. The study focused on the 
effect of these two proteins on the expressions of MDR1 /P-glycoprotein as well as 
HI 9, based on the previous finding that HI 9 knockdown affect 
MDRl/P-glycoprotein expression (chapter 2). 
It was then found that, upon knockdown of PTB, MDR 1 /P-glycoprotein was 
upregulated. On the other hand, IMPl knockdown decreased MDR 1 /P-glycoprotein 
expression. Meanwhile, HI9 RNA in PTB knockdown cells was declined but 
elevated in IMPl knockdown cells (Table 3.1). The antagonistic effect of IMPl and 
PTB might be related to the fact that these two RNA-binding proteins virtually bind 
to their target molecules in a competitive manner. Exclusive binding might affect the 
stability of their target RNA molecules. However, whether PTB and IMPl affect HI 9 
and MDRl in transcriptional level or post-transcriptional level, for instances, RNA 
turnover, RNA processing or translation efficiency, has not yet been investigated. 
Because IMPl and PTB interact with HI9 RNA directly, it is reasonably thought that 
they affect HI9 in post-transcriptional level. Since HI9 most likely affect MDRl in a 
transcriptional level, we suggest that PTB and IMPl might affect MDRl at 
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transcriptional level, perhaps through HI9. 
3.4.2 Complexity of riboregulation 
The inter-relationship between PTBl, IMP, HI9 and MDRl has been examined 
in this and the previous chapter. It has been demonstrated that the change of either 
PTB, IMP or HI9 did have influence on MDRl expression. It seems that both HI9 
and IMPl can be a positive regulator of MDRl. That is, when either HI9 or IMPl 
level is inhibited, the MDRl expression declines accordingly. If HI9 or IMPl were 
able to regulate MDRl independently, it is hard to explain why inhibition of IMPl 
downregulated MDRl and simultaneously upregulated HI9, as over-expression of 
HI9 were supposed to infer drug resistance by upregulating MDRl. In addition, 
knockdown of PTB also decreased HI9 but upregulated MDRL Again it is 
contradictory to the assumption that low level of HI9 should suppress MDRl 
expression. 
To explain this phenomenon, a model of cooperative regulation is proposed. It is 
assumed that either IMPl or HI9 alone is not able to regulate the expression of their 
target gene (in this case, MDRl). However, when both molecules are present, 
probably by forming a functional RNA-protein complex, they are capable of 
modulating the expression of their target gene. Thereby, knockdown of either factor 
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(HI9 or IMPl) prevents formation of the functional complex, and hence suppresses 
the expression of their target gene. Then it is not surprised that why knockdown of 
IMPl increased HI9 but not MDRl, because knockdown of IMPl did not favour the 
formation of a putative “functional RNA-protein complex", even if in the presence of 
a lot of HI9 RNA. Actually, this “cooperative” model is not so simple in real 
situation. The mature HI9 RNA is 2.3 kb long. RNA binding proteins like IMPl or 
PTB only interact with a small fragment of the RNA. Indeed, HI9 RNA is able to 
recruit more than two RNA binding proteins, as revealed by UV-crosslinking assay 
(Chapter 4). The formation of the bulky complex in vitro by HI9 RNA and its 
interacting partners was revealed in a native gel by using gel shift assay, as discussed 
in the next chapter. Therefore, the proposed "cooperative" model might not only 
involve HI9 RNA and IMPl, but might involve other unknown factor(s) that act 
together to perform the regulation process. 
The model that HI9 and IMPl form a functional complex that positively 
regulates MDRl still cannot explain the results of PTB RNAi experiment. In PTB 
RNAi experiment, knockdown of PTB decreased HI9 RNA level, but increased 
MDRl expression. According to the proposed model, low level of HI9 RNA does 
not favour the formation of HI9 complex, so that MDRl expression should be 
repressed. Actually, the situation of riboregulation might be far more complicated 
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than we expected, and it could be a dynamic process that involves different factors at 
different subcellular localization in different stages. PTB is a nuclear protein that 
normally presents in nucleus, particularly in perinucleolar compartment (Wang et al. 
2003). It is known to associate with pre-mRNAs and affect their fate of processing. 
On the other hand, IMPl presents in the cytoplasm. It is thought to bind mature 
RNAs and help to direct their subcellular localization (Nielsen et al. 1999). In view 
of the different functions of IMPl and PTB, these two RNA binding proteins might 
play a different role, perhaps through different pathway, in mediating H19-related 
MDRl expression. 
There are still many questions remain to be answered. Firstly, if the proposed 
model is correct, how many proteins will associate with HI9? Are IMPl and PTB the 
only HI 9 binding protein? If not, are there any other novel interacting partners? Thus, 
the study of RNA-protein interaction is important to help answer these questions. 
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CHAPTER FOUR 
Identification of H19 RNA Binding Proteins from 
Human Hepatocellular Carcinoma HepG2 Cells 
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4.1 Introduction 
4.1.1 Overview of RNA-protein interactions 
Similar to DNA in chemical structure and as an information carrier, RNA 
molecules show a greater diversity in secondary structure. Many RNAs in cells fold 
into globular structure with minimal free energy, in the view of energetics that such 
structure is most stable (Draper et al. 2005). 
In eukaryotic cells, RNA molecules rarely exist in a free form. It has now been 
known that many RNA molecules form complexes with other molecules. 
Immediately after biosynthesis in nucleus by RNA polymerase, the nascent RNA 
transcripts associate with a group of heterogeneous ribonucleoproteins to form the 
heterogeneous ribonucleoprotein particles (hnRNP). The hnRNP proteins may assist 
in pre-RNA processing and transport of mRNAs. All pre-mRNAs, except histone 
mRNAs, are cleaved at specific 3' site and polyadenylated to generate a poly(A) tail. 
The process of 3’ end cleavage and polyadenylation involves binding of different 
factors, for examples, CPSF (cleavage-and-polyadenylation specificity factor) and 
PAP (poly-A polymerase). Most eukaryotic pre-mRNAs undergo RNA splicing as a 
strategy to generate different protein isoforms. RNA splicing is a dynamic process 
that involves interactions between pre-mRNA, snRNA (small nuclear RNA) and 
different splicing factors such as U2AF and snRNPs (small nuclear ribonucleoprotein 
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particles). In cytoplasm, mature mRNA is directed to a distinct region for special 
purpose like translation. In the translation machinery (ribosome), rRNA interacts 
with ribosomal proteins, and cooperates with mRNA and tRNA to form a bulky 
functional complex for the synthesis of peptide bonds, most likely catalyzed by 
rRNA(Soller 2006). 
In some specialized organelles, for instances, the mitochondria of protozoans 
and chloroplasts in plants, a rare type of RNA processing called RNA editing is 
performed to further change the RNA sequence, perhaps as an alternative strategy for 
generating different forms of proteins. RNA editing involves another non-coding 
RNA category called gRNA (guide RNA) and the RNA-editing enzymes known as 
deaminases (Shikanai 2006). 
For all the sorts of RNA biochemistry, RNA-protein interactions play a central 
role in the proper functioning of biologically active RNA molecules. RNA-RNA and 
RNA-DNA interactions might help the process but these interactions usually play 
supplementary roles. 
The HI9 non-coding RNA shares common properties with those coding 
mRNAs in RNA processing like RNA splicing, 5’ cap formation and polyadenylation. 
However, the non-coding property of HI9 makes it different from mRNAs in 
functioning. In the previous chapter, it was shown that its putative RNA-binding 
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proteins, IMPl and PTB, had effect on the expression of HI9 as well as the 
H19-related MDRl expression. In light of this phenomenon, RNA-protein 
interactions between HI9 RNA and cellular proteins were studied in this chapter. 
4.1.2 Methodology in the study of RNA-protein interactions 
Different techniques have been developed for studying RNA-protein 
interactions. Some techniques are virtually derived from DNA-protein interaction 
protocols, based on the similar biochemistry of RNA and DNA. However, assays for 
RNA experiments generally require more cautious consideration when designing and 
doing experiments, as a trace amount of nuclease contamination would lead to 
tremendous degradation of RNA. 
Biochemical analysis of RNA-protein interactions requires sensitive detection 
of RNA molecules. For this purpose, radioactive labeling of RNA molecules by in 
vitro RNA transcription provides a good method for sensitive detection of a trace 
amount of RNA specimen. Labeled RNA probes can be used for the study of RNA 
binding, RNase protection or RNA processing etc, depending on the purpose of study. 
In this chapter, RNA gel shift assay (or sometimes called RNA electrophoretic 
mobility shift assay) was used to study the ability of HI9 RNA to associate with 
proteins. When RNA forms complex with proteins, it moves slower in a native gel 
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due to the bulky size. This provides basic information about RNA-protein 
interactions. To further characterize the number and approximate molecular size of 
RNA-interacting proteins, UV-crosslinking assay is a common and efficient method 
for this purpose. Short wavelength UV light at 254 nm provides sufficient energy to 
covalently crosslink RNA and protein in close contact. Crosslinked proteins become 
"labeled" as the labeled RNA probes bond to them. As a result, RNA-binding 
proteins could be analyzed in a denaturing gel. Sometimes, immunoprecipitation of 
the crosslinked proteins is applied together with UV-crosslinking assay as a 
supplementary protocol to confirm the identity of the crosslinked proteins. However, 
this method usually requires prior information of the RNA-binding proteins. It is not 
applicable when the RNA-interacting partners are totally unknown. 
4.1.3 Identification of RNA-binding proteins 
When information on RNA-interactions has been obtained, it becomes 
important to identify and characterize the particular RNA binding protein(s). 
Identification of RNA-binding proteins would involve different techniques with 
different advantages and disadvantages, based on the methodology of experimental 
design. 
One of the approaches is to screen the RNA-binding proteins from a cDNA 
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expression library. This method, also known as Northwestern screening, make use of 
a labeled RNA probe to screen the possible interacting candidates from a cDNA 
expression library. Success of this method depends on the diversity of the library and 
optimization of binding condition. The advantage of Northwestern screening is that 
the genetic information of the RNA-binding proteins can be easily obtained from the 
？L-phage plasmid. However, construction of a cDNA library is labour intensive and 
false clones would usually be obtained. 
The yeast two-hybrid system for studying protein-protein interactions has also 
been modified to a "three-hybrid" system for the study of RNA-protein interactions. 
In the three-hybrid system, the RNA hybrid is composed of an RNA bait and an RNA 
tag, which is specifically recognized by an RNA binding domain. The RNA-binding 
domain fused with a DNA-binding domain to form the second hybrid. The third 
hybrid is composed of the novel RNA-binding protein and an activation domain that 
drive the expression of the reporter gene, for exmple, lac Z. The yeast three-hybrid 
system gains advantage in an in vivo interaction environment, but might also produce 
many false results. 
The last but not the least approach is to use an RNA affinity chromatography 
method. In this method, the RNA bait is tagged into a resin to form the RNA affinity 
column. Partially purified protein lysate is passed through the column and the 
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trapped proteins are identified by either protein sequencing or mass spectrometry. 
There are several methods for preparing the RNA column. One is to covalently 
couple the RNA bait to CNBr-activated Sepharose. However, covalent coupling of 
RNA at the "active site" may hinder the subsequent binding of proteins. The second 
method is to incorporate biotinylated nucleotides into the RNA so that the 
biotinylated RNA bait can bind to streptavidin-coated matrix. The binding affinity is 
high but the biotin group might affect the RNA's secondary structure that is critical 
for RNA-protein interactions. The third method of preparing an RNA affinity column 
is to make use of the poly-A tail on the RNA bait. Since HI9 RNA possesses a 
naturally occurring poly-A tail, this tail can be annealed to the poly-dT-coated 
cellulose resin. The naturally occurring poly-A tail does not affect the RNA 
conformation and is also unlikely to hinder the binding of proteins to the “active site" 
of the RNA. Despite of this advantage, the Watson-Crick base pairing between the 
poly-A tail and the poly-dT resin is not so strong that RNA bait can easily shed off 
from the column. Thereby, the salt concentration of the binding buffer should be 
carefully adjusted that allows strong RNA annealing and RNA-protein interactions. 
In this chapter, RNA gel shift assay and UV-crosslinking assay were used to 
study HI9 RNA-protein interactions. Subsequently, RNA-affinity chromatography 
was used to isolate the potential H19-binding proteins. 
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4.2 Materials and methods 
4.2.1 Materials 
Chemicals/Reagents Company/Supplier 
a-32p UTP (3000 Ci/mmol) Amersham Biosciences 
Acetonitrile Sigma 
Acrylamide/bisacrylamide Bio-Rad 
Agarose In vitro gen 
ammonium bicarbonate Sigma 
Ammonium persulphate (APS) Sigma 
Ampicillin Sigma 
Benchmark Prestained protein marker Invitrogen 
Chloroform BDH Laboratory Suppliers 
Coomassie Blue Bio-Rad 
Diethyl pyrocarbonate (DEPC) Sigma 
DTT Sigma 
E. coli tRNA Sigma 
EDTA USB 
Ethanol Scharlau 




Isoamyl alcohol Sigma 
Isopropanol MERCK 
Magnesium chloride Sigma 
Matrix (a-cyano-4-hydroxycinnamic acid) Sigma 
MEGAscript T7 kit Ambion 
Ndel restriction enzyme NEB 
01igo(dT)-cellulose Amersham Biosciences 
Phenol USB 
Plasmid mini-preparation kit Viogene 
Phenylmethysulfonylfluorid (PMSF) Boehringer Mannheim 
QIAEX II DNA extraction kit Qiagen 
Rapid-Screen Arrayed cDNA library (human placenta) Origene 
RNA ladder (0.5-10kb) Invitrogen 
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RNase A Sigma 
RNase inhibitor Promega 
RNase T1 Roche 
Sodium acetate Sigma 
TEMED Invitrogen 
Trifluoroacetic acid Sigma 
Trypsin (sequencing grade, modified) Promega 
Trypsin with EDTA Invitrogen 
Turbo DNasel Ambion 
Xbal restriction enzyme Transgenomics 
For other chemicals or reagents used in Western blot analysis, please refer to 
Chapter 2.2.1. 
Antibodies Company/Supplier 
anti-CRDBP/IMPl antibody Santa Cruz 
anti-Goat IgG HRP-conjugate Zymed 
anti-Mouse IgG HRP-conjugate Zymed 
anti-PTB antibody Zymed 
Culture wares Company/Supplier 
96-well flat bottom culture plate Nunc 
100-mm culture dish Iwaki 
Instruments/Equipments Company/Supplier 
3-MM filter paper Whatman 
Del Drier Savant 
Bounce homogenizer Wheaton 
ElutaTube Fermentas 
Film cassette Kodak 
MALDI Mass Spectrometer with nano LC system Applied Biosystems 
Microplate reader Molecular Device 
Mini-Protean II electrophoresis apparatus Bio-Rad 
Scintillation Counter LS3801 Beckman 
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Speed Vac System Savant 
Table Top Ultracentrifuge TLX-120 Beckman 
Trans-Blot SD semi-transfer cell Bio-Rad 
UVP CLIOOO Cabinet Crosslinker SW UVP 
X-ray film Fuji 
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4.2.2 Methods 
4.2.2.1 Screening of H19 cDNA from human placenta cDNA library 
The HI9 cDNA clones were screened from a human placenta cDNA library 
subplate (LLPC8C) by using a pair of HI 9 specific primers: 
Forward: 5,-TAC AAC CAC TGC ACT ACC TG-3’ 
Reverse: 5’-TGG AAT GCT TGAAGG CTG CT-3, 
96-well PCR was performed as: denaturation at 94°C for 30 sec, annealing at 
60°C for 30 sec, extension at 72°C for 90 sec; the reaction was cycled 35 times and 
the result was revealed in 1.5% agarose gel. Bacterial stock from one of the positive 
wells (A 10) was spreaded on a LB agar plate and 96 clones were randomly picked 
for colony PCR with the same PCR condition. Positive clones were sequenced and 
the clone carrying the longest HI9 cDNA (clone 68) was used for the subsequent 
study. 
4.2.2.2 Preparation of nuclear and cytoplasmic extracts from HepG2 cells 
HepG2 cells were trypsinized and resuspended in cold PTB. Cells were pelleted 
by centrifugation at 3000 rpm for 2 minutes. Cell pellets were quickly resuspended in 
5 packed cell volume (pcv) of hypotonic buffer (10 mM Hepes pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.2 mM PMSF, 0.5 mM DTT). Cells were centrifuged at 3000 
78 
rpm for 5 minutes at 4�C , and supernatant was discarded. The packed cells were then 
resuspended in hypotonic buffer to a final volume of 3 times pcv, and cells were 
allowed to swell on ice for 10 minutes. Swollen cells were transferred to a glass cell 
homogenizer and homogenized with ten up-and-down strokes. Lysed cells were 
transferred to a centrifuge tube and nuclei were collected by centrifugation at 4000 
rpm for 15 minutes at 4�C. The supernatant was saved for cytoplasmic extract 
preparation. The packed nuclei volume (pnv) was measured and the nuclei was 
resupspended in 1/2 pnv of low-salt buffer (20 mM Hepes pH 7.9，25% glycerol, 1.5 
mM MgCl2, 20 mM KCl, 0.2 mM EDTA，0.2 mM PMSF, 0.5 mM DTT). An equal 
volume (1/2 pnv) of high-salt buffer (20 mM Hepes pH 7.9, 25% glycerol, 1.5 mM 
MgCl2, 0.8 M KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT) was then added 
dropwise, and the nuclei was allowed to extract for 30 minutes on ice with occasional 
gentle mixing. The extracted nuclei were centrifuged at 14,000 rpm for 30 minutes at 
4�C. The supernatant (nuclear extract) was collected. 
For the preparation of cytoplasmic extract, the saved supernatant after cell 
homogenization was added with 0.11 volume of lOX cytoplasmic extract buffer (0.3 
M Hepes pH 7.9, 1.4 M KCl, 30 mM MgCl�）and mixed thoroughly. The supernatant 
was then subjected to ultracentrifugation at 100,000 g (using TLA120.2 rotor) for 1 
hour at 4°C. The supernatant (cytoplasmic extract) was collected. 
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Both nuclear and cytoplasmic extracts were dialyzed in more than 50 volumes 
of dialysis buffer (20 mM Hepes pH 7.9, 10% glycerol, 80 mM KCl, 0.2 mM EDTA, 
0.2 mM PMSF, 0.5 mM DTT) at 4�C before subjected to functional assay. Dialysis 
was performed by using ElutaTube dialysis tubes. Protein extracts were stored at 
-70�C if not used immediately. 
4.2.2.3 In vitro RNA transcription and RNA labeling 
The pCMV6-XL4 vector containing HI9 cDNA was linearized by Ndel (5, end) 
and Xbal (3 ’ end) restriction enzymes. After digestion, the restriction enzymes were 
heat inactivated at 65°C for 20 minutes. Digested DNA was separated in 0.8% 
agarose gel and the fragment containing HI9 cDNA and the 5' flanking T7 promoter 
was cut from the gel and extracted by Qiagen's DNA extraction kit. The DNA 
template was eluted in nuclease-free dHiO and concentrated in vacuum. In vitro 
RNA transcription was carried out by using Ambion's MEGAscript® T7 kit. In each 
20 |Lil reaction, 1 |j,g DNA template was added to the transcription mixture containing 
IX transcription buffer, 7.5 mM ATP, CTP, UTP and GTP and 2 jiil T7 enzyme mix. 
The reaction mixture was incubated at 37�C for 4 hours. Transcription was stopped 
by the addition of lU DNasel and a further incubation at 37°C for 15 minutes to 
digest the DNA template. RNA was extracted by phenol/chloroform method and 
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precipitated by isopropanol. After precipitation, RNA pellet was washed with 0.5 ml 
75% ethanol and dried in air. The RNA pellet was dissolved in nuclease-free dH20 
and stored at -70°C • RNA concentration was estimated by spectrophotometry. The 
size of the synthesized RNA was checked by running 1 jug of the denatured RNA in a 
1% agarose gel. 
For radioactive labeling of RNA, the concentration of ATP, CTP and GTP was 
lowered to 0.5 mM, while UTP was lowered further to 0.1 mM, and 60 |iCi a - P 
UTP (3000 Ci/mmol) was added to the 20 jil reaction. This produced high specific 
activity of RNA molecules with an average of 10% uridine being labeled. The 
activity of the labeled RNA was determined by scintillation counting. 
4.2.2.4 RNA electrophoretic mobility shift assay 
The binding mixture was set up on ice by mixing 14 jul binding buffer (20 mM 
Hepes pH 7.9, 10% glycerol, 80 mM KCl，0.2 mM EDTA, 0.2 mM PMSF, 1 mM 
DTT), 1 |Lil MgCl2 (80 mM), 1 |al E.coli tRNA (10 mg/ml), 20 j^ g cytoplasmic extract 
and nuclease-free dH20 to a final volume of 24 The mixture was pre-incubated at 
30�C for 8 minutes followed by addition of 1 jiil radiolabeled RNA (1 x 10^ cpm) 
and a further incubation of 15 minutes at 30°C • In RNA competitive binding 
experiment, various amount of cold HI9 RNA was pre-incubated with the 
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cytoplasmic extract at 30�C for 10 minutes before the addition of hot RNA. The 
binding mixture was then chilled on ice for 2 - 3 minutes and loaded to a 4% native 
polyacrylamide gel. Electrophoresis was run in 45 mM Tris-borate running buffer at 
200V for 4 hours in cold room. The gel was dried at 80�C for 1 hour under vacuum 
pump and the RNA-protein complexes were revealed by autoradiography. 
4.2.2.5 In vitro UV-crosslinking assay 
Binding condition was set up as in RNA electrophoretic mobility shift assay. 
The binding mixture was incubated at room temperature for 20 minutes. After 
incubation, the mixture was transferred to a pre-chilled 96-well plate kept on ice. The 
plate was placed in a UV light box and irradiated with UV light (254 nm) for 20 
minutes. After UY-crosslinking, the samples were treated with 10 |j.g RNaseA and 
25U RNase T1 at 37°C for 30 minutes to digest excess and uncrosslinked probes. 
The crosslinked samples were then mixed with equal volume of 2X SDS protein 
sample buffer and denatured by boiling for 10 minutes. After denaturation, the 
samples were loaded to a 12% SDS-PAGE gel and run at 200 V for 50 minutes. The 
gel was dried at 80 °C for 1 hour under vacuum pump and the bands of 
RNA-crosslinked proteins were revealed by autoradiography. 
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4.2.2.6 Preparation of RNA-affinity column and isolation of RNA binding 
proteins 
Oligo-dT cellulose of 0.5 ml bed volume was equilibrated in 1 ml RNA 
annealing buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 M NaCl) before use. 
0.5 mg of in vitro prepared HI9 RNA was dissolved in 1 ml RNA annealing buffer. 
The RNA solution was heated to 60°C for 5 minutes and then applied to the oligo-dT 
cellulose. The RNA solution was allowed to anneal to the cellulose for 30 minutes at 
room temperature with gentle rotation. After incubation, the cellulose was spun down 
and washed with annealing buffer. The amount of RNA annealed to the cellulose was 
calculated as the difference between the total input RNA and the amount of RNA 
remained in the eluted buffer. The RNA-annealed cellulose was equilibrated in 
binding buffer (20 mM Tris-HCl pH 7.5，50 mM KCl，3 mM MgCb, 5% glycerol, 
0.5 mM EDTA, 1 mM DTT). 
For isolation of RNA binding proteins, 0.5 mg cytoplasmic extracts was 
adjusted to a final volume of 1 ml with binding buffer. The extract was added with 
0.4 mg E. coli tRNA and lOOU RNase inhibitor and incubated at room temperature 
for 10 minutes. Then, the protein extract was applied to the RNA-annealed cellulose 
and incubated at 4°C for 1 hour with gentle rotation. After incubation, unbound 
protein was eluted and the matrix was washed with 20 bed volumes of binding buffer. 
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Bound proteins were eluted from the column by 0.5 ml elution buffer (20 mM 
Tris-HCl pH 7.5, 2 M KCl). Elution step was repeated three times and the eluted 
fractions were combined. The eluted proteins were desalted by dialysis and 
concentrated by Speed Vac at 4°C. Concentrated proteins were dissolved in SDS 
sample buffer and heat denatured by boiling for 10 minutes. Denatured proteins were 
resolved in 12% SDS-PAGE and stained with Coomassie Blue. 
4.2.2.7 In-gel digestion and MALDI-TOF mass spectrometry 
The bands of the isolated RNA binding proteins resolved in SDS-PAGE gel 
were cut and chopped up into small slices. Gel slices were washed overnight with 
wash solution (50% methanol, 5% acetic acid) and then dehydrated with 200 jul 
acetonitrile. Dehydrated gel slices were dried and reduced by 30 \i\ of 10 mM DTT 
for half hour at room temperature. After reduction, gel slices were added with 30 
of 100 mM iodoacetamide and incubated at room temperature for half hour to 
alkylate proteins. Reduced and alkylated proteins in gels were dehydrated again with 
200 [i\ acetonitrile and rehydrated in 200 )LI1 of 100 mM ammonium bicarbonate. 
Dehydration-rehydration steps were repeated once to remove residual DTT and 
iodoacetamide in gels. Finally, dried gel slices were incubated with 30 \i\ trypsin 
solution (20 |Lig/ml in 50 mM ammonium bicarbonate) and in-gel trypsin digestion 
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was allowed to proceed at 37�C overnight. 
After in-gel digestion, peptides were extracted by 30 of extraction buffer 
(50% acetonitrile, 5% formic acid). Extraction step was repeated and the peptide 
extracts were combined, dried and re-dissolved in 10 |LI1 0.1% trifluoroacetic acid. 
Peptides in 0.1% trifluoroacetic acid were purified by chromatography using ZipTip. 
Purified peptides were eluted in 50% acetonitrile solution. For mass spectrometric 
analysis, 0.5 jul peptide solution was mixed with 0.5 \i\ matrix 
(a-cyano-4-hydroxycinnamic acid) and spotted on wells of a MALDI stainless steel 
plate. Samples were dried and subjected to MALDI-TOF MS/MS analysis. The 
results were analyzed by searching in SWISS-PROT (homo sapiens) database using 
GPS Explorer TM software (Applied Biosystems). 
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4.3 Results 
4.3.1 Screening of H19 cDNA and preparation of H19 RNA 
The human HI9 mRNA is 2.3 kb long. It is one of the hard-to-clone genes as 
there is a guanosine rich sequence residing on its 5’ end. The in vitro study for HI9 
RNA-protein interactions requires a functional HI9 cDNA construct for RNA 
synthesis. At the beginning of the study, the HI 9 cDNA was screened from a human 
placenta cDNA library. Placenta library was chosen because HI9 is abundantly 
expressed in placenta. HI9 specific primers were designed for 96-well PCR. As a 
result, many wells showed positive result, which represents the presence of HI9 
cDNA in these wells. Bacterial stock from one of positive wells was spreaded on LB 
agar plate and a total of 96 colonies were further screened by colony PCR. Among 
the 96 colonies picked, 7 colonies showed positive result. Plasmids in these colonies 
were extracted and subjected to DNA sequencing in both 5' and 3' ends. One colony 
contained the longest HI9 cDNA, and this clone was fully sequenced. 
The vector carrying HI9 is a mammalian expression vector pCMV6-XL4 
(Figure 4.1 A). There is a T7 promoter sequence upstream of HI9 cDNA. This 
promoter sequence can be used for in vitro RNA synthesis catalyzed by recombinant 
T7 bacteriophage RNA polymerase. However, the circular plasmid cannot be used 
directly in in vitro transcription, as the lack of transcriptional termination signal at 
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the end of HI 9 DNA. Thus, the plasmid must first be linearized at both ends of HI 9 
cDNA with the retention of the T7 promoter sequence. Linearized HI9 DNA was 
then used for run-off in vitro transcription. For radiolabeling of HI9 RNA, ^^P-UTP 
was added to the transcription reaction. The produced HI9 RNA was randomly 
labeled, with an average of 10% uridine being labeled. High specific activity of RNA 
probe was required for the subsequent UV-crosslinking analysis because only a short 
sequence of the RNA molecule will crosslinked with proteins. The radiolabeled RNA 
transcripts were checked for correct molecular size and integrity on a denaturing 
agarose gel, before they were used for RNA binding assays (Figure 4.1 B). 
4.3.2 Electrophoretic mobility shift analysis of HI9 RNA with HepG2 
cytoplasmic extract 
To test whether HI9 RNA associates with proteins in cytoplasmic extracts, RNA 
electrophoretic mobility shift assay was performed. Labeled HI9 RNA was mixed 
with cytoplasmic extract at 30°C (30°C is the optimal temperature for in vitro 
RNA-protein binding) for 15 minutes and then chilled on ice for 2 to 3 minutes. The 
samples were then run on a 4% non-denaturing polyacrylamide gel. If RNA forms 
complex with protein(s), the RNA-protein complex will move slower in the electric 
field than the free RNA alone. It was shown that in the presence of cytoplasmic 
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Figure 4.1 In vitro transcription and radiolabeling of H19 RNA. (A) Vector 
map of pCMV6-XL4 which carries the HI9 cDNA. The HI9 cDNA was screened 
from a human placenta cDNA library by 96-well PCR using HI9 specific primers. 
The plasmid was linearized by restriction digestion at Ndel and Xbal. After 
digestion, the HI9 cDNA fragment with an upstream T7 promoter sequence was 
gel purified and used as a template for T7 in vitro transcription. (B) Synthesis of 
radiolabeled HI9 RNA by in vitro transcription. HI9 RNA was labeled by random 
incorporation of ^^P-UTP during RNA transcription. After transcription, the DNA 
template was removed by DNasel and the RNA product was precipitated and 
dissolved in nuclease free water. The size and the integrity of the synthesized RNA 
were checked on a 1% RNA denaturing gel. The band of RNA was revealed by 
autoradiography. 
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extract, the RNA moves slower, probably due to the formation of RNA-protein 
complex (Figure 3.2, Lanes 1, 2). Since the crude cytoplasmic extract is a collection 
of different proteins, some might be non-specific RNA binding proteins. To examine 
the possibility of non-specific binding, unlabeled HI 9 RNA was added to the binding 
mixture as a specific competitor. If the binding of cellular proteins to the labeled 
RNA probe is specific, the addition of non-labeled specific RNA competitor will 
reduce the binding of proteins to the labeled RNA. As a result, more labeled RNA 
probe was “free”. This phenomenon was observed in our experiment when increasing 
amount of cold HI9 RNA was added (Figure 4.2，Lanes 4-7). Therefore, the binding 
of cellular protein(s) to HI 9 RNA should be specific. 
4.3.3 UV-crosslinking of HI9 RNA with HepG2 nuclear and cytoplasmic extract 
Although HI9 was able to form complex with cellular proteins, as revealed in 
the RNA gel shift assay, the information on how many cellular proteins interact with 
HI9 RNA is not yet available. UV-crosslinking assay is a common method used to 
reveal the number of proteins capable of binding the RNA probe. To do this, RNA 
binding condition was set up as before. After incubation of labeled RNA with 
cytoplasmic or nuclear extracts, the samples were irradiated with short wavelength 
UV light (254 nm). If RNA and protein molecules are in close contact, UV light will 
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Figure 4.2 Electrophoretic mobility shift analysis of HI9 RNA with HepG2 
cytoplasmic extract. H19 RNA probe (1 x 10^  cpm) was incubated with 20 jug 
HepG2 cytoplasmic extract at 30�C for 15 minutes in presence of 3.2 mM MgCl� 
(lane 2,3). In RNA competitive binding experiment, increasing amount of cold 
HI9 RNA (lane 4-7) was pre-incubated with cytoplasmic extract before the 
addition of hot RNA. RNA-protein complex was chilled on ice and then run in a 
4% non-denaturing polyacrylamide gel in cold room. Gel was dried and revealed 
by autoradiography. 
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provide energy for the formation of covalent bonds between the nucleosides and the 
amino acids. After UV treatment, excess probes were digested by RNase A and 
RNase Tl，so that the crosslinked proteins will be more "clean" with as little effect as 
in their molecular sizes. Crosslinked proteins were dissolved in SDS buffer and heat 
denatured, and finally resolved in a protein gel. The RNA-crosslinked proteins were 
revealed by autoradiography. From Figure 4.3，it was found that HI9 RNA was able 
to crosslink with at least two nuclear proteins and 2 cytoplasmic proteins. Two major 
proteins, both present in the nuclear and cytoplasmic extracts, bound to HI9 RNA. 
The identities of these HI9 binding proteins were unknown. However, PTB (MW 
59.6 kDa) and IMPl (69 kDa) are the two possible candidates, according to the 
previous publication (Runge et al. 2000). The major band with an approximate 
molecular size of 60 kDa (Figure 4.3, lower black arrow) might be PTB, based on the 
similar molecular size and its predominant nuclear localization. The light band 
observed only in the cytoplasmic extract (Figure 4.3，upper red arrow, approximate 
MW: 70 kDa) might be IMPl, because IMPl is known to be a cytoplasmic protein 
(Nielsen et al. 1999). The two nuclear proteins with molecular size ranged from 80 
kDa to 110 kDa (Figure 4.3, white arrows) were unknown from literature. In addition, 
the other major band with high molecular size (upper black arrow) was observed 
both in nuclear and cytoplasmic extracts. The identities of these unknown proteins 
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Figure 4.3 UV-crosslinking of H19 RNA with HepG2 nuclear and cytoplasmic 
extract. H19 RNA probe (1 or 2 x 10^  cpm) was incubated with 20 jag HepG2 
nuclear or cytoplasmic extract for 20 minutes at room temperature. RNA-protein 
complex was crosslinked by UV light (254 nm) for 20 minutes on ice. Excess RNA 
probes were digested with 10 fig RNaseA and 25U RNase T1 at 37°C for 30 
minutes. Proteins were heat denatured and resolved in 12% SDS-PAGE gel. The 
gel was dried and bands were revealed by autoradiography. The white arrows 
indicate nuclear proteins crosslinked to HI9 RNA. The red arrows indicate 
cytoplasmic protein crosslinked to HI9 RNA. The black arrows indicate HI9 RNA 
binding proteins both present in nuclear and cytoplasmic extracts. NE: nulcear 
extract; CE: cytoplasmic extract. 93 
await to be characterized. 
4.3.4 Isolation of H19 RNA binding proteins by RNA-affinity chromatography 
To identify those unknown H19 RNA binding proteins, an RNA-affinity column 
was prepared. Plenty amount of HI9 RNA was generated by in vitro transcription. 
The RNA was annealed to oligo-dT coated cellulose, and cytoplasmic extract was 
allowed to bind to RNA. Unbound proteins were washed while bound proteins were 
eluted with high salt buffer that dissociates RNA-protein interactions. Eluted proteins 
were desalted, concentrated and finally resolved in an SDS-PAGE gel (Figure 4.4). 
The eluted proteins actually were not as clear as expected. It is a mixture of 
RNA-binding proteins, oligo-dT binding proteins, cellulose binding proteins as well 
as those proteins being trapped in the pores of the resin. To tackle this problem, a 
background control was set up with no RNA being annealed to the resin. As a result, 
those bands emerged in the background control reflected those non-RNA specific 
binding proteins. From Figure 4.4，it was observed that at least four bands were 
present only in the eluted proteins from HI9+ column, as indicated by black arrows 
in the figure. The proteins in these bands might be the possible HI9 binding proteins. 
However, those bands present in both HI9+ and HI9- elutants could also be possible 
HI9 RNA binding proteins, in case that their molecular sizes are overlapping with 
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Figure 4.4 Isolation of H19 RNA binding proteins by RNA-affinity 
chromatography. HI9 RNA-affinity column and HepG2 cytoplasmic extract were 
prepared as described in Materials and Methods. Cytoplasmic extract was 
incubated with HI9 RNA-annealed oligo-dT-cellulose (HI9+) or with oligo-dT-
cellolose (HI9-) for an hour at 4�C. RNA bound proteins were eluted by high salt 
buffer. After desalting and concentration, samples were denatured and separated 
on a 10% SDS-PAGE gel. The arrows indicate eluted proteins only present in 
HI9+ column. M: protein marker. 
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the background binding proteins. 
4.3.5 Confirmation of PTB and IMPl as H19 RNA binding protein 
So far in this study, no evidence was provided to confirm the binding of PTB 
and IMPl to HI9 RNA, although such experiment has been done by other group 
(Runge et al. 2000). To test whether PTB and IMPl bind H19 RNA in the system of 
the present study, eluted proteins from HI9+ and HI9- columns were probed with 
anti-PTB and anti-CRDBP (IMPl) antibodies. Results from Western blot analysis 
revealed the presence of both proteins in HI9+ elutant (Figure 4.5). Nevertheless, a 
trace amount of PTB and IMPl was still observed in the HI9- elutant. The presence 
of a little PTB and IMPl proteins in H19-null column should not reflect the 
background binding proteins. Instead, these proteins might be due to the unexpected 
pull-down of endogenous HI 9 RNA-protein complexes in the crude protein extract. 
4.3.6 MALDI-TOF mass spectrometric analysis of isolated HI9 RNA binding 
proteins 
In seeking to identify novel HI9 RNA binding proteins that might be related to 
the regulatory function of HI9，the identity of those bands emerged in HI9+ elutant 
(Figure 4.4) was identified by matrix-assisted laser desoption ionization time of 
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Figure 4.5 Western blot analysis of isolated H19 RNA binding proteins. Eluted 
proteins from HI9+ or HI9- column were resolved in 12% SDS-PAGE gel and 
transferred to a nitrocellulose membrane. The membrane was probed with anti-
PTB and anti-CRDBP (IMPl) antibodies. Chemiluminescent signal was developed 
by ECL method. H19+: proteins eluted from HI9 RNA-annealed oligo-dT-cellose; 
H19-: proteins eluted from oligo-dT-cellulose. 
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flight mass spectrometry (MALDI-TOF MS). Accordingly, four bands 
(arrow-indicated in figure 4.4) were cut and in-gel digested by trypsin. Trypsin 
digested peptides were analyzed by MS/MS and data were compared to the database 
SWISS-PROT of homo sapiens. One of the bands with approximate 80 kDa MW 
(second arrow from top) was successfully identified to be polyadenylate-binding 
protein 1 (PABPl, accession no. PI 1940) or heterogeneous nuclear ribonucleoprotein 
M (hnRNP M, accession no. P52272). PABPl has a molecular size of 70 kDa, which 
is not matched with the observed 80 kDa in the SDS-PAGE gel. hnRNP M has a 
molecular size of 77 kDa, which is close to our observed protein. Literature review 
found that hnRNP M has two isoforms with molecular size of 77 kDa and 80 kDa 




4.4.1 RNA-protein interactions: An initial step for mechanistic study 
The objective of this chapter is to study the underlying mechanism of 
riboregulation, using HI9 as a model. Probably, the understanding of RNA-protein 
interactions might be the very first step for this purpose, as regulatory RNAs perform 
their functions through interaction with proteins. For example, the recent discovered 
microRNA (miRNA) is found to interact with different proteins to perform its 
regulatory function. The primary miRNA transcript is first processed to pre-miRNA 
by Drosha (an RNase III enzyme). Pre-miRNA is further processed by Dicer, another 
RNase III enzyme, to become the mature miRNA. Mature miRNA associates with a 
group of proteins, for instance, Argonaute proteins, to form the miRNA-associated 
multiprotein RNA-induced silencing complex (miRISC). It is this functional 
RNA-protein complex that regulates a wide range of target mRNAs. In light of this 
mechanism, it is important to understand the RNA-protein interactions for the novel 
H19-mediated riboregulation. It is hoped that understanding of such interactions 
would provide insight into the diverse functions of non-coding transcripts observed 
in mammalian transcriptome. 
Using in vitro RNA-binding assays, it was shown that HI9 RNA was able to 
form stable complex with cellular proteins. By RNA gel shift assay, we observed the 
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formation of such bulky complex when RNA was incubated with cytoplasmic extract. 
Using the lowest percentage of polyacrylamide gel, the free HI9 RNA was able to 
move in the gel, while the complex moved slowly. After 4 hours of electrophoresis, 
the complex was found to move for a very short distance from the loading well. 
When gel shift assay was performed in even lower percentage of agarose gel, similar 
result was observed (data not shown). The phenomenon may be due to the formation 
of a bulky RNA-protein complex. Given that the full-length HI9 RNA transcript was 
2.3 kb long (equivalent to � 7 4 0 kDa), and the molecular sizes of the possible HI9 
RNA binding proteins ranged from 60 kDa to more than 200 kDa, as revealed by the 
UV-crosslinking assay, the complex could be more than 1,000 kDa, not to mention 
about protein-protein interactions in the complex! As a result, conventional gel shift 
assay is not very applicable for studying full-length HI9 RNA-protein interactions. 
One alternative approach is to divide the HI9 RNA into many short fragments, so 
that intermediate size of the complex can be formed and successfully “shifted” in 
gels. However, such approach was not adopted in the present study since 
fragmentation of HI9 RNA may disrupt its biological integrity, based on the 
assumption that the secondary structure of biologically active non-coding RNA is 
critical for its proper function. Despite this difficulty, our result does not affect the 
conclusion that HI9 is able to form complex with cellular proteins. 
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Another common RNA-binding assay, filter binding assay, which is not adopted 
in the study, can also be applied to study RNA-protein interactions. In filter binding 
assay, proteins bound to RNA probes are retained on a nitrocellulose filter membrane, 
while those unbound RNA will pass through the filter. The amount of bound 
RNA-protein complex could be detected and quantified. This provides a quantitative 
method for measuring RNA-binding affinity. However, gel shift assay still shows 
advantages in visualization of RNA-protein complex and sometimes for detecting 
sequential and cooperative binding. 
4.4.2 In vitro and in vivo methods for isolation of RNA binding proteins 
In order to isolate specific HI9 RNA binding proteins, RNA affinity 
chromatography was used in the study. The binding condition was empirically 
determined in gel shift and UV-crosslinking assays. However, in vitro RNA-protein 
binding might not accurately mimic the in vivo RNA-protein interactions, although 
many RNA interacting proteins have been successfully identified using the in vitro 
methods (Czyzyk-Krzeska & Bendixen 1999; Patel et al. 2005; Tanguay & Gallie 
1996). 
Some methods have been designed to study the in vivo RNA-protein 
interactions. The yeast three-hybrid system (as described in the introduction of this 
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chapter) is developed for this purpose. However, when using this system for isolating 
RNA interacting proteins, one should consider the variation in the in vivo 
environment between yeast and mammalian cell. Immunoprecipitation of in vivo 
formed RNA-protein complex may provide a good alternative method for in vivo 
study. This could only be used when at least one of the interacting proteins is known. 
The RNA binding protein recognized by the antibody should also bind to the RNA of 
interest specifically. Otherwise the co-immunoprecipitated proteins might be false 
results. So far to our knowledge in HI9 RNA binding proteins, neither IMPl nor 
PTB bind to HI9 specifically. The former can bind IGF2 mRNA and probably c-myc 
mRNA. The latter even binds to a wide range of different mRNA (reviewed in the 
introduction of Chapter 5). That is why immunoprecipitation was not adopted in this 
study. 
Perhaps, a possible in vivo identification of HI9 binding proteins can be 
developed to meet this requirement. This method, although not yet developed, 
virtually gains insight from the "tagging strategy" widely used in protein-protein 
interactions study. It is possible to engineer the HI9 RNA by adding a short RNA tag 
at either 5' or 3' end. This RNA tag can be recognized by specific "antibody" that can 
be used to pull down the in vivo formed RNA-protein complex. A natural 
RNA-recognizing “antibody，，，the phage MS2 coat protein, can recognize a short 
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RNA MS2 sequence with high specificity and affinity. Therefore, this special type of 
"immunoprecipitation" can be employed to isolate in vivo formed RNA-protein 
complex, without the problem of pulling down background proteins. 
4.4.3 Novel role of hnRNP M protein in HI9 RNA binding 
Using mass spectrometry, another RNA binding protein was isolated from the 
HI9 RNA affinity column. This protein, named as heterogeneous nuclear 
ribonucleoprotein M (hnRNP M), has not been reported to bind HI9 RNA. Literature 
review found that this protein belongs to the a group of hnRNPs, which directly bind 
to nascent RNA polymerase II transcripts and plays an important role in both 
transcript-specific packaging and pre-mRNA alternative splicing. Interestingly, PTB 
(also known as hnRNP I) also belongs to this group of RNA binding proteins. The 
reason why PTB and hnRNP M bind to HI9 RNA is unknown. In fact, only limited 
knowledge is known about this protein. One of the significant finding on hnRNP M 
protein is about its carcinogenetic role in cancer biology (Laguinge et al. 2005b). 
Although hnRNP M was originally known to be a nuclear protein, surface expression 
of its homolog on the plasma membrane was observed. This RNA binding protein 
was found to be able to bind CEA (carcinoembryonic antigen) and help localization 
of CEA antigens. Bajenova et al found that hnRNP M protein has two isoforms with 
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molecular weight of 80 and 76 kDa. The long form (80 kDa) has cytoplasmic 
localization and is expressed on membrane. The short truncated form (76 kDa) has 
nuclear localization (Bajenova et al. 2003). Based on this information, we suggested 
that the hnRNP M protein isolated in our experiment should be the surface expressed 
long form, since the observed size is apparently about 80 kDa (Figure 4.4). 
The relationship between hnRNP M，H19 and CEA is unknown. Carcinogenetic 
property of CEA is similar to H19. Whether the function of H19 is related to CEA 
needs to be further explored. Given that hnRNP M is able to bind CEA and HI9 
RNA, it is interestingly to know whether hnRNP M could act as a “linker molecule" 
to pull CEA and HI9 RNA together to form a functional complex. 
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CHAPTER FIVE 
The Role of PTB in Apoptosis 
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5.1 Introduction 
5.1.1 Overview of polypyrimidine tract-binding protein in RNA processing and 
post-transcriptional gene regulation 
Polypyrimidine tract-binding protein (PTB) is a 59.6 kDa nuclear RNA binding 
protein which is widely expressed in different tissues. It belongs to a group of 
nuclear RNA-binding proteins called heterogeneous nuclear ribonucleoproteins 
(hnRNP), which has been known to regulate alternative pre-mRNA splicing. So PTB 
is also known as hnRNP I (Ghetti et al. 1992). It has four RRM domains that bind 
consensus sequence UCUUC or CUCUCU, and an N-terminal domain with nuclear 
localization signal (Perez et al. 1997; Wagner & Garcia-Blanco 2001). The four 
RRM domains of PTB possess high affinity for binding pyrimidine-rich context. 
Therefore, PTB is able to bind polypyrimidine tract (PPT) of the 3’ splice site of 
regulated exon, and hence represses splicing by competing with splicing factor 
U2AF65 for the PPT (Lin & Patton 1995; Singh et al. 1995). Genes which alternative 
spliced exons being repressed by PTB include: exon 7 of P-tropomyosin, exon N of 
GABAy2, exons Illb and IIIc of FGF-R2, exon N1 of c-src, exon SM of a-actinin, 
exon 9 of caspase-2, exon M2 of immunoglobulin M and exon 9 of CFTR. 
In addition to act as a splicing repressor, PTB also plays an important role in 
recruiting internal riobosome entry segment (IRES) in the 5'-untranslated region 
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(UTR) of mRNA to the ribosome. While most mRNA translation is initiated at the 5' 
cap site, some mRNAs contain an IRES sequence located in the 5' UTR. PTB is one 
of the RNA-binding proteins that bind IRES to help recruitment of ribosome to the 
internal site of mRNA. This unusual type of translation initiation is widely employed 
by some viral RNA using an alternative strategy for favouring viral mRNA 
translation. Not surprisingly, PTB was reported to be able to interact with a number 
of viral RNAs including FMDV (foot and mouth disease virus) (Luz & Beck 1991; 
Niepmann et al. 1997), EMCV (encephalomyocarditis virus) (Kaminski et al. 1995), 
HAV (hepatitis A virus) (Schultz et al. 1996)，HCV (hepatitis C virus) (Ali & 
Siddiqui 1995) and poliovirus (Hellen et al. 1994), and was a critical factor for viral 
mRNA translation. Besides viral RNA, PTB can interact with many host mRNA, 
usually in the 5' UTR region, and consequently affect their translation efficiency. 
Some of the genes played a critical role in apoptosis, like Apaf-1, Bag-1. 
PTB also plays other roles in RNA metabolism. Firstly, PTB was reported to 
regulate the processing of 3'-terminal sequence by repressing both splicing and 
polyadenylation of a-tropomyosin in Xenopus oocyte (Le Sommer et al. 2005)or 
inhibiting 3'-end cleavage of pre-mRNA (Castelo-Branco et al. 2004). Secondly, 
PTB cooperates with other RNA-binding proteins and affects mRNA stablility by 
forming a stable ribonucleoprotein complex (Singh et al. 2004). Thirdly, PTB 
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mediates Vgl mRNA cytoplasmic transport and localization that is important for 
generating cell polarity during development (Cote et al. 1999). 
5.1.2 Evidences of polyrimidine-tract binding protein in the regulation of 
apoptosis 
Although the vast roles of PTB have been described, only a small proportion of 
documents discuss about the role of this RNA-binding protein in apoptosis. In this 
section, the role of PTB in apoptosis will be briefly reviewed. 
Apoptosis is a tightly regulated biochemical process that involves activation of a 
family of cysteine proteases called caspases, and mitochondrial depolarization by 
members of Bcl-2 family. Depending upon the source of apoptotic signals, apoptosis 
can be classified into intrinsic and extrinsic pathways, whilst both pathways share 
common central effector caspase-3 which activation results in execution of apoptosis 
such as chromatin condensation, DNA fragmentation and apoptotic body formation. 
The mechanism of regulation of apoptosis is a complicated process that might 
involve proteolytic cleavage of proteins and/or transcriptional activation or silencing 
of apoptotic genes. In most apoptosis-related post-transcriptional regulation, 
alternative pre-mRNA splicing and IRES-facilitated mRNA translation played an 
important role. Recently, post-transcriptional regulation of anti-apoptotic gene Bcl-2 
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by microRNA (miR-15 and miR-16) was reported (Calin et al. 2002; Cimmino et al. 
2005), suggesting that the process of programmed cell death should employ different 
mechanisms of regulation. 
Although numerous reports have been published to demonstrate the roles of 
PTB in pre-mRNA splicing repression, exon silencing, IRES-facilitated mRNA 
translation and mRNA stability, the physiological function of PTB is still unclear. 
While basal PTB is expressed in most tissues except in normal neuronal cells, it was 
observed that this protein was overexpressed in some neuronal tumors (McCutcheon 
et al. 2004). Whether PTB plays a role in neoplastic trasnsformation or progression is 
yet needed to be confirmed. Another role of PTB is implicated by the observation 
that this protein was involved in the regulation of apoptosis genes. Known genes of 
apoptosis that was regulated by PTB alone or co-regulated with other regulators 
include Apaf-1 (Mitchell et al. 2003), Fas (Izquierdo et al. 2005), Bag-1 (Pickering et 
al. 2004) and caspase-2 (Cote et al. 2001; Cote et al. 2001; Jiang et al. 1998). 
Interestingly, PTB itself is also regulated by active caspase-3 (Back et al. 2002). 
During apoptosis induction, caspase-3 is activated and the active caspase-3 fragment 
is translocated into the nucleus (Kamada et al. 2005). Since PTB is a nuclear protein, 
it is probably cleaved by active caspase-3 inside the nucleus. The consequence of 
PTB cleavage during apoptosis is not clear, but it is speculated that in the absence of 
109 
PTB the expressions of some of the apoptotic genes will be altered. To test this 
hypothesis, PTB was knocked down by RNA interference in HepG2 cells and its 
effect on apoptosis induced by various stimuli was assayed. 
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Agarose In vitro gen 
Annexin-V-GFP Provided by Dr. Kong from 
Dept. of Biochemistry, CUHK 
Aprotinin Sigma 
Caspase-3 inhibitor z-DQMD-fmk MERCK 
Caspase-3 colorimetric substrate I MERCK 
Caspase-8 inhibitor z-IETD-fmk MERCK 
Caspase-9 inhibitor z-LEHD-fmk MERCK 
Caspase-9 colorimetric substrate II MERCK 
CHAPS (3-[(3-cholamidopropyl)dimethyllammoninio] USB 
-propanesulfonate) 
Chloroform BDH Laboratory Suppliers 
DNA ladder marker (100 bp) Invitrogen 








Isoamyl alcohol Sigma 
Leupeptin Amersham Biosciences 
Phenol USB 
Propidium iodide (PI) Sigma 
PMSF Boehringer Mannheim 
Proteinase K Sigma 
RNase A Sigma 
Sodium dodecyl sulphate (SDS) Invitrogen 
Sodium acetate Sigma 
Sodium chloride USB 
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TNF-a Calbiochem 
Tris base USB 
Trypsin with EDTA Invitrogen 
For other chemicals or reagents used in cell culture, MTT drug sensitivity assay 
and Western blot analysis, please refer to Chapter 2.2.1. 
Antibodies Company/Supplier 
anti-P-actin antibody Sigma 
anti-Bax antibody Santa Cruz 
anti-Bcl-2 antibody MERCK 
anti-Bcl-xL antibody Santa Cruz 
anti-Bid antibody Santa Cruz 
anti-Caspase-3 antibody Santa Cruz 
anti-Caspase-8 antibody Stressgen 
anti-Caspase-9 antibody Stressgen 
anti-Goat IgG HRP-conjugate Zymed 
anti-ICAD antibody Santa Cruz 
anti-MDRl/P-glycoprotein antibody Oncogene 
anti-Mouse IgG HRP-conjugate Zymed 
anti-PARPl antibody Santa Cruz 
anti-PTB antibody Zymed 
anti-Rabbit IgG HRP-conjugate Zymed 
Culture wares Company/Supplier 
96-well flat bottom culture plate Nunc 
3 5-mm culture dish TPP 
60-mm culture dish TPP 
100-mm culture dish Iwaki 
Instruments/Equipments Company/Supplier 
FACSort flow cytometer Becton Dickinson 
Film cassette Kodak 
Gammacell 3000 Elan Irradiator MDS Nordion 
Microplate reader Molecular Device 
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Mini-Protean II electrophoresis apparatus Bio-Rad 
Trans-Blot SD semi-transfer cell Bio-Rad 
UV transilluminator U ^ P 
X-ray film Fuji 
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5.2.2 Methods 
5.2.2.1 Cell culture 
HepG2 cells and its RNAi sublines were cultured as described in Chapter 2.2.2. 
The human squamous carcinoma A431 cells were cultured in Dulbecco modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 5 mM 
L-glutamate in 37�C humidified 10% CO2 incubator. The A431 RNAi sublines were 
cultured in the same condition except that 400 |Lig/ml G418 was added to the 
medium. 
5.2.2.2 Stable cell transfection in A431 cells 
Methods for stable cell transfection in A431 cells were similar to that of HepG2 
cells except that medium supplemented with 10% FBS was used for cell culture. 
5.2.2.3 Western Blot analysis 
Refer to Chapter 2.2.2 for methods in Western blot analysis. 
5.2.2.4 MTT drug sensitivity assay 
Refer to Chapter 2.2.2 for methods in MTT drug sensitivity assay. 
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5.2.2.5 DNA fragmentation assay 
Cells were grown in 60 mm culture dish for 2 days and then treated with 
different concentrations of drugs or caspase inhibitors and then incubated for 2 days 
with Taxol, DOX and 丫-radiation，or 3 days with TNF-a treatment. Cells were 
trypsinized, washed with IX PBS and then lysed in lysis buffer containing 5 mM 
Tris-HCl, 100 mM EDTA, 1% SDS and proteinase K at 4 5 f o r 2 hours. The DNA 
was extracted by phenol/chloroform/isoamyl alcohol (25:24:1) and precipitated in 
70% ethanol at -20°C overnight. DNA pellet was collected by centrifugation at 14000 
rpm for 35 minutes and dissolved in Tris-EDTA buffer (pH 8.0) with 0.4 jug/ml 
RNase A and digested at 37°C for 3 hours. Equal amount of DNA was resolved on 
1.5 % agarose gel containing 0.05 |ig/ml ethidium bromide and visualized under UV 
transilluminator. 
5.2.2.6 Flow cytometry analysis of apoptosis 
After 2 days of different concentrations of Taxol treatment, cells were washed 
and collected in PBS and stained with 5 jul Annexin-V-GFP fusion protein and 1 
mg/ml PI in binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCh) for 15 
minutes at room temperature in dark. Cells were analyzed by FACSort flow 
cytometer and subsequently the graphs were produced by software WinMDI 2.8. 
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5.2.2.7 Caspase activity assay 
Cells with or without Taxol treatment were trypsinized and washed with cold 
PBS. About 1 million of cells were lysed with 25 jiil non-denaturing lysis buffer (50 
mM Hepes, pH 7.4，100 mM NaCl, 10 |Lig/ml leupeptin, 5 |ig/ml aprotinin, 100 |aM 
PMSF, 0.1 mM EDTA, 0.1 mM DTT, 0.1 % CHAPS) and placed on ice for 10 
minutes followed by centrifugation at 14000 rpm for 10 minutes at 4 The 
supernatant was assayed by BCA Protein Assay Reagents and were stored in -70 °C 
or used to perform assay immediately. Caspase activity assay was performed by 
adding 25 |LI1 crude protein lysate to 75 j^ l reaction buffer (50 mM Hepes, pH 7.4，100 
mM NaCl, 50 mM EDTA, 10 mM DTT, 0.1% CHAPS, 10% glycerol) and 10 i^l 
caspase substrates (2 mM) in 96-well plate and incubated at 37 °C for 3 hours. The 
relative activity of caspases was measured by the increase of absorbance in 405 nm 
as normalized by the crude protein concentration. 
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5.3 Results 
5.3.1 Taxol as an apoptosis inducer in HepG2 cells 
Taxol (or paclitaxel) is an anti-cancer drug that is clinically used for the 
treatment of breast, ovary and lung cancers. It inhibits depolymerization of 
microtubules and hence causes cell cycle arrest. It has also been indicated that Taxol 
is able to induce programmed cell death in cancer cells by binding to Bcl-2 and thus 
arresting its anti-apoptotic function. Therefore, Taxol was used as an apoptosis 
inducer in my study. 
Activation of caspase-3 is the hallmark of apoptosis. Proteolytic cleavage of 
pro-caspase-3 by initiator caspases such as caspase-8, 10, 9 results in execution of 
apoptosis. Apoptotic cells demonstrate chromatin condensation, DNA fragmentation 
and apoptosis body formation. To see whether Taxol was able to induce apoptosis in 
HepG2 cells, the cells were treated with 20 nM Taxol or DMSO as solvent control 
for 24, 48 and 72 hours. Cells were lysed and analyzed by Western blot analysis and 
caspase-3 activity assay (Figure 5.1 A). Western blot analysis showed that the 
pro-caspase-3 level was decreased upon treatment of Taxol. Meanwhile caspase 
activity assay showed five folds activation of caspase-3 activity when cells were 
treated for 48 hours, and declined afterwards. 
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5.3.2 PTB was cleaved during Taxol-induced apoptosis 
To see whether PTB is involved in apoptosis, we investigated the level of PTB 
by Western blot anaysis. It was observed that during Taxol-induced apoptosis, PTB 
level was reduced, most significantly after 48 hours drug treatment (Figure 5.IB). 
This is coincident with the maximum caspase-3 activation. If PTB reduction is due to 
the activation of caspase-3, inhibition of caspase-3 should maintain PTB level. 
Therefore, when cells were pre-treated with 30 [iM caspase-3 inhibitor 
(z-DQMD-fmk), Taxol had no effect the level of PTB (Figure 5.IB). The decline of 
PTB is caspase-3 dependent and probably due to proteolytic degradation of the 
protein by activated caspase-3 during apoptosis (Back et al. 2002). 
5.3.3 PTB knockdown increased Taxol cytotoxicity and apoptosis 
The decline of PTB during Taxol-induced apoptosis might implicate a specific 
role of this protein in the regulation of apoptosis. The consequence of PTB depletion 
in apoptosis is unknown. In order to study the role of PTB in apoptosis, a stable 
HepG2 subline (GPi) was developed by using RNAi. The PTB level in GPi subline 
was greatly reduced, as compared with the parent HepG2 cells (G) or the RNAi 
control subline (C) which constitutively expressed GFP-shRNA (Figure 5.2A). By 
MTT assay, it was found that the Pi cells were more sensitive to Taxol (Figure 5.2A). 
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Figure 5.1 The effect of Taxol-induced caspase-3 activation on PTB expression 
level. (A) HepG2 cells were treated with 20 nM Taxol to induce apoptosis. Cells 
were lysed after 24, 48 and 72 hours of Taxol treatment. Total proteins were 
extracted for Western blot analysis and caspase-3 activity assay. For Western blot 
analysis, denatured proteins were probed with polyclonal anti-caspase-3 antibody. 
For caspase-3 activity assay, native protein extract was incubated with chromogenic 
caspase-3 substrate at 37°C for 3 hours. Relative activity of caspase was measured 
by the increase of absorbance in 405 nm. Mean 土 S.E.M. from 3 independent 
experiments. (B) HepG2 cells were treated with 20 nM Taxol alone or with 30 \iM 
caspase 3 inhibitor (z-DQMD-fmk) for 24, 48 and 72 hours. Total proteins were 
extracted and probed with monoclonal anti-PTB and anti-P-actin antibodies. 
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To test whether this phenomenon is due to the increased programmed cell death, 
apoptosis assays were performed. By flow cytometry, the percentage of dead cells 
was quantitated when the 3 cell lines were treated with increasing concentration of 
Taxol. Consistent with MTT assay, more GPi cells underwent apoptosis than the 
control cells (Figure 5.2B). DNA fragmentation assay also showed a greater extent of 
DNA fragmentation in Pi cells (Figure 5.2C). 
5.3.4 Effect of PTB knockdown on drug sensitivity of cells 
Although the effect of PTB silencing on Taxol sensitivity is prominent, the 
effect of this protein in response to other drugs or cytokines await investigating. By 
MTT assay, GPi cells were more sensitive to DOX than the parent HepG2 cells or 
RNAi control cells, in agreement with Taxol. In contrast, GPi cells were more 
resistant to 5-flurouracil and 丫-radiation. In addition, GPi cells were also more 
resistant to cytokines such as TNF-a and interferon-丫 (Figure 5.3). These data 
suggest that PTB might play a role in drug sensitivity, but the mechanism is unclear. 
5.3.5 Effect of PTB knockdown on other drug-induced apoptosis 
Apart from Taxol, the effect of GPi on apoptosis induced by other drugs/agents 
was also investigated. It was found that both DOX and y-radiation induced a greater 
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Figure 5.2 The effect of PTB Knockdown on drug sensitivity and apoptosis 
upon Taxol treatment. (A) PTB was knocked down in HepG2 cells by RNAi. 
Cells were transfected with RNAi vector expressing PTB-specific shRNA driven 
by human U6 RNA pol III promoter (GPi). Cells transfected with a GFP-specific 
shRNA was used as an RNAi control (C). G is the parent HepG2 cells. After 
establishment of stable transfectants, cells were lysed and probed with PTB 
antibodies by Western blot analysis. For MTT assay, cells were seeded on 96-well 
plate and treated with various concentrations of Taxol for 2 days. Survival cells 
were measured by MTT dye reduction. Mean 土 S.E.M. from 3 independent 
experiments. (B) Apoptosis of GPi cells was measured by flow cytometry. Cells 
were treated with increasing concentration of Taxol for 48 hours. After drug 
treatment, cells were washed and stained with PI and Annextin-V, and then 
analyzed in a flow cytometer. The proportion of apoptotic cells were analyzed by 
FACSort. (C) Apoptosis of GPi cells was measured by DNA fragmentation assay. 
After 48 hours of Taxol treatment, genomic DNA was extracted and DNA 
fragmentation was revealed on an agarose gel. 
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Figure 5.3 Effect of PTB knockdown on DOX, 5-fluorouracil, y-radiation, 
TNF-a and IFN-y sensitivity in HepG2 cells. Cells were plated in 96-well plates 
for 2 days followed by treatment of various concentrations of drugs for another 2 
days (DOX, 5-fluorouracil, y-radiation) or 3 days (TNF-a and IFN-y). Survival cells 
were assessed by MTT dye reduction. Percentage survival of cells was calculated as 
the proportion of viable cells with drug treatment to those cells without drug 
treatment. G: HepG2 parent cells; C: RNAi control cells; GPi: PTB RNAi cells. 
Mean 土 S.E.M. from 3 independent experiments. 
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extent of DNA fragmentation in GPi cells than that of parent or control cells (Figure 
5.4 A, B). Both DOX and y-ray are DNA-damaging agents that are able to induce 
apoptosis. However, when cells were treated with TNF-a, PTB silencing had no 
effect on TNF-a-induced apoptosis (Figure 5.4 C). TNF-a is a cytokine that induces 
apoptosis in a signaling pathway different from DOX and Taxol. This suggests that 
PTB might affect apoptosis in certain specific pathway. 
5.3.6 Effect of PTB knockdown on the basal expressions of genes in apoptosis 
pathway 
The apoptosis pathway involves a number of proteins that interact with each 
other to achieve programmed cell death. These proteins include the family of 
cysteine proteases called caspases, the mitochondrial Bcl-2 family proteins, 
inhibitors of apoptosis proteins (lAPs) and the caspase-3 downstream proteins 
(PARP-1, ICAD). The effect of PTB on the expression of these proteins was 
analyzed by Western blotting. In PTB knockdown cells, the basal expression of 
pro-caspase-9 was upregulated, while Bcl-2 was downregulated (Figure 5.5). 
Pro-caspase-9 is an initiator caspase that activates downstream caspase-3 by forming 
a complex called apoptosome, and Bcl-2 is an anti-apoptotic mitochondrial protein 
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Figure 5.4 The effect of PTB knockdown on apoptosis induced by DOX, y-
radiation and TNF-a in HepG2 cells. Cells were treated with various 
concentrations of DOX or TNF-a, or irradiated with various doses of 丫-radiation. 
After 48 hours (DOX, y-radiation) or 72 hours (TNF-a), genomic DNA of cells was 
extracted, and DNA fragmentation was revealed in agarose gel. G: HepG2 parent 
cells; C: RNAi control cells; GPi: PTB knockdown cells. 
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critical role in the regulation of intrinsic pathway. Therefore, PTB probably regulate 
apoptosis by controlling the level of pro-caspase-9 and Bcl-2 in the intrinsic pathway. 
5.3.7 The role of caspase-9 activation in PTB-regulated apoptosis 
Since PTB knockdown resulted in an elevation of pro-caspase-9 level and hence 
increased drug-induced apoptosis (Figure 5.2, 5.5 & 5.7), a rationale for the role of 
pro-caspase-9 in PTB-regulated apoptosis was reasoned. Therefore, the relative 
caspase-9 activity in GPi cells was compared with the parent HepG2 or control cells 
upon Taxol treatment. Caspase activity assay showed that caspase-9 was activated in 
all three cell lines upon Taxol treatment and the activation is more significant in the 
GPi cells (Figure 5.6 A). Subsequently, when GPi cells were pre-treated with 15 jiiM 
caspase-9 inhibitor, the level of Taxol-induced DNA fragmentation was significantly 
reduced and was comparable to the parent or control cells without treatment of 
caspase-9 inhibitor (Figure 5.6 B). On the other hand, inhibition of caspase-8 by 15 
I^ M caspase-8 inhibitor also reduced Taxol-induced DNA fragmentation, but the 
effect on apoptosis for caspase-8 inhibitor treatment was not as significant as that for 
caspase-9 inhibitor treatment (Figure 5.6 C). These data confirm the role of caspase-9 
in PTB-regulated apoptosis. 
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Figure 5.5 The effect of PTB knockdown on basal expressions of apoptotic 
genes. Proteins from HepG2 parent cells (G)，RNAi control cells (C) and PTB 
knockdown cells (GPi) were extracted and subjected to Western blot analysis. (A) 
Proteins were probed with PTB and P-actin antibodies. (B) Proteins were probed 
with pro-caspase-3, pro-casapse-8 and pro-caspase-9 antibodies. (C) Proteins were 
probed with Bcl-2, Bc1-Xl, Bax and Bid antibodies. (D) Proteins were probed with 
ICAD and PARPI antibodies. 
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Figure 5.6 The effect of caspase-8 and caspase-9 inhibitions on Taxol-induced 
apoptosis in HepG2 PTB knockdown cells. (A) Caspase-9 activities of HepG2 
cells and PTB knockdown cells as induced by Taxol was measured by caspase 
activity assay. Cells were treated with 20 nM Taxol for 24, 48 and 72 hours. Crude 
protein lysates were extracted and assayed for caspase-9 activity. The relative 
caspase-9 activity was calculated as the fold changes to the control treatment 
(HepG2 parent cells without Taxol treatment was set as control). (B) The effect of 
caspase-9 inhibition on Taxol-induced apoptosis in PTB knockdown cells. Cells 
were treated with various concentrations of Taxol and with or without 15 |iM 
caspase-9 inhibitor for 48 hours. Genomic DNA was extracted and revealed in 
agarose gel. Mean 土 S.E.M. from 3 independent experiments. (C) The effect of 
caspase-8 inhibition on Taxol-induced apoptosis in PTB knockdown cells. DNA 
fragmentation assay was performed as in (B) except that cells were incubated with 
15 [iM caspase-8 inhibitor. G: HepG2 parent cells; C: RNAi control cells; GPi: PTB 
knockdown cells. 
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5.3.8 The effect of PTB knockdown on pro-caspase-9 expression and 
Taxol-induced apoptosis in A431 cells 
While the role of PTB in the regulation of caspase-9 and drug-induced intrinsic 
apoptosis pathway has been studied in HepG2 cells, one of the questions still needs 
to be addressed is whether the role of PTB in apoptosis is cell line specific. To 
address this question, another human squamous carcinoma cell, A431，was used. By 
employing the same method, individual PTB RNAi sublines were developed in A431 
cells. Two clones of PTB knockdown A431 sublines (APi) were successfully 
developed (Figure 5.7 A). These two clones showed undetectable level of PTB by 
Western blotting. Meanwhile, pro-caspase-9 was also upregulated in the A431 APi 
cells. Similarly, when the APi cells were treated with 6 nM Taxol (A431 cells are 
generally more sensitive to Taxol than HepG2 cells), the cells displayed more DNA 
fragmentation than the parent A431 or control cells (Figure 5.7 B). Since PTB 
inhibition in HepG2 cells also downregulates Bcl-2, this effect was also investigated 
in A431 cells. However, it was found that the basal level of Bcl-2 in A431 cells was 
greatly reduced. As a result, the role of PTB in the regulation of Bcl-2 was 
insignificant in A431 cells (Figure 5.7 C). 
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Figure 5.7 The effect of PTB knockdown on Taxol-induced apoptosis in A431 
cells. A431 cells were transfected with shRNA-expressing vector targeting PTB 
(APi) or GFP (AC) and stable RNAi tmasfectants were selected by G418. (A) Basal 
proteins of individual transfectants were extracted and probed with PTB, pro-
caspase-9 and P-actin antibodies by Western blot analysis. (B) Both clone 2 of RNAi 
control cells and PTB knockdown cells were used for DNA fragmentation assay. 
Cells were treated with 6 nM Taxol for 2 days. Genomic DNA was extracted and 
DNA fragmentation was revealed in agarose gel. (C) Basal expressions of PTB, pro-
caspase-9, Bcl-2 and P-actin in HepG2 and A431 cells by Western blot analysis. 
Basal proteins of HepG2 and A431 cells were extracted and probed with PTB, 
caspase-9, Bcl-2 and P-actin antibodies and its corresponding secondary antibodies. 
AP: A431 parent cells; AC: RNAi control cells in A431; APi: PTB knockdown cells 
in A431; G: HepG2 parent cells. 
135 
5.3.9 The role of PTB in the regulation of intrinsic apoptosis pathway 
In general, PTB knockdown in both HepG2 and A431 cell lines promotes 
drug-induced apoptosis by upregulation of pro-caspase-9 and probably Bcl-2. Figure 
5.8 summarizes the role of PTB in regulation of the intrinsic pathway of apoptosis. 
There was an exceptional case that TNF-a treatment had no effect on PTB-regulated 
apoptosis. This might be due to the distinct mechanism of TNF-a in apoptosis 
induction. And this will be discussed in the end of this chapter. 
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Figure 5.8 Schematic diagram describing the role of PTB in the regulation of 
the intrinsic apoptosis pathway by altering pro-caspase-9 and probably Bcl-2. 
The PTB level was cleaved by active caspase-3 during apoptosis. Low level of PTB 
increased pro-caspase-9 level and might decrease Bcl-2. Increased pro-caspase-9 
and decreased Bcl-2 level favoured the progression of mitochondrion-dependent 
apoptosis. This "caspase-3 — PTB — caspase-9 / Bcl-2 -> caspase-3，，feedback 
pathway provides an amplified death signal that drives apoptosis forwards. 
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5.4 Discussion 
5.4.1 The role of PTB in intrinsic apoptosis pathway 
In an initial attempt to study the role of PTB in the mediation of H19-regulated 
MDRl expression, a stable cell line with PTB silenced by RNAi was established 
from HepG2 cells. This cell line, as a model for the study of biochemical changes in 
PTB deficiency, was found to be more sensitive to Taxol, a commonly used 
anti-cancer drug. Since Taxol has been documented to induce apoptosis in various 
cancer cells, it is reasoned that the increased Taxol sensitivity might be due to the 
increased programmed cell death in PTB deficient state. Therefore, apoptosis assays 
were performed to test this hypothesis. By using Annexin-V apoptosis assay, which 
measures phosphatidylserine extemalization (a characteristic of apoptosis) during 
early apoptosis, more cell death was observed in PTB knockdown cells. This was 
also in agreement with the results from DNA fragmentation assay. In addition, the 
level of PTB was decreased during Taxol-induced apoptosis, while inhibition of 
caspase-3 activity restored PTB level. It is therefore thought that PTB might play a 
role in apoptosis. Further study illustrated that the pro-caspase-9 level was increased 
whilst Bcl-2 was reduced in PTB knockdown cells. Both alterations favour the 
progress towards execution of apoptosis. Similar result was also observed in another 
cell line, human squamous carcinoma A431 cell. To test whether the enhancement of 
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apoptosis was due to caspase-9 upregulation in PTB knockdown cells, caspase-9 
inhibitor was added to inhibit the activity of caspase-9. As a result, these PTB 
knockdown cells showed less apoptosis, and the degree of apoptosis was comparable 
to that of the parent or control cells. It seems apparent that in the low level of PTB, 
pro-caspase-9 is upregulated so that the cells were more vulnerable to intrinsic 
apoptosis inducer. On the other hand, since PTB knockdown had no effect on the 
expression of pro-caspase-8 (an initiator caspase in the extrinsic apoptosis pathway), 
treatment of TNF-a showed no advantage in facilitating apoptosis. Taking all the 
present data together, PTB is thought to be one of the regulators in the intrinsic 
apoptosis pathway. 
5.4.2 PTB in regulation of pro-caspase-9 expression 
Although PTB has been intensively studied in RNA metabolism, only a few 
reports have been published to discuss the role of this protein in the regulation of 
apoptosis. Therefore, not much information is known so far. In my study, negative 
control of capsase-9 by PTB was illustrated by using RNAi. The relationship 
between PTB and caspase-9 has not been reported by other groups. Caspase-9 is a 
mitochondrion-depedent initiator caspase that will, upon activation, activate the 
downstream caspase-3. On the other hand, PTB is a nuclear RNA-binding protein 
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that has been shown to affect RNA processing such as alternative splicing, 
IRES-mediated mRNA translation as well as mRNA stability. So it is proposed that 
PTB might regulate pro-caspase-9 expression at the "RNA level". There are two 
transcript variants, alpha- and beta- for pro-caspase-9 mRNA. The alpha 
pro-caspase-9 mRNA consists of 9 spliced exons and both 5' and 3' untranslated 
regions. The shorter beta variant lacks the middle exon-3, 4，5，6, but maintains the 
same reading frame as the alpha variant (the translational product of the beta mRNA 
is anti-apoptotic, as opposite to the alpha protein). The beta mRNA is formed due to 
alternative splicing of pre-caspase-9 mRNA. Whether PTB has effect on the 
alternative splicing of caspase-9 yet needs to be approved. However, sequence 
analysis of casapase-9 mRNA discovered several PTB-binding consensus sequences 
(UCUUC and CUCUCU) residing on exon-2, exon-5, exon-6 and exon-9. Since 
exon-5 and exon-6 are omitted in the beta variant of caspase-9 mRNA, it might be 
interesting to know whether the two PTB-binding consensus sequences on these two 
exons might be critical for the alternative splicing of the pre-mRNA. Further study 
will be focused on the RNA-protein interaction of PTB and caspase-9 mRNA. In 
vitro mRNA splicing assay may provide good evidence for studying the role of PTB 
in caspase-9 alternative splicing. Other mechanism such as PTB-dependent mRNA 
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6.1 H19 as a potential target in anti-cancer gene therapy 
HI9 overexpression has been implicated in tumor progression and invasion 
(Ayesh et al. 2002). In the present study, HI9 overexpression is likely to confer drug 
resistance, at least in liver cancer cells. This raises the issue that HI9 could be a 
potential target for gene therapy, as knockdown of HI9 RNA will sensitize cells to 
chemotherapeutic drugs and perhaps inhibit tumor growth. Since HI9 RNA is not 
required for normal function in normal cells (except in muscle cells), HI9 could be a 
good target for gene therapy for some HI9 expressing tumors, for example, the liver 
cancers. Perhaps, new drugs can be designed to specifically inhibit the expression of 
HI9 RNA or block its functional activity. Possible approaches include: i) delivery of 
HI9 specific siRNA to the H19-expressing tumors. The development of 
siRNA-based gene therapy has been advanced in recent years (Devi 2006); ii) 
delivery of antisense oligos to specifically block the functional sequence in HI9, 
perhaps by preventing the formation of a functional RNA conformation or 
RNA-protein complex; iii) inhibitors to inhibit the transcription of HI9. For all the 
approaches, a better understanding of the inside molecular mechanism is required 
before the design of the potential drugs. Despite its identification in literature for 
more than two decades, the molecular mechanism downstream to HI9 is poorly 
understood. This has hampered the development of drugs for targeting HI9. The 
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present study focused on the regulatory relationship between HI9 and MDRl, as 
well as the role of HI9 RNA binding proteins played in this process. Although the 
information provided by the end of this study is very limited, it might direct the 
future study into the right track and provides basic information of anti-cancer drug 
design. 
6.2 Conclusion 
The present study has provided partial information for the picture of HI9 
downstream pathway. In this study, HI9 has been demonstrated to interact with a 
nuclear (PTB) and a cytoplasmic (IMPl) RNA binding protein (Chapter 4). 
Knockdown of either PTB or IMPl changed the H19 RNA level. The effect of the 
two RNA binding proteins on HI9 expression is opposite to each other (Chapter 3). 
The MDRl expression level, which is thought to be regulated by HI9 RNA (Chapter 
2), was also affected by knockdown of either of the RNA binding proteins (Chapter 
3). Again, the effect of the two RNA binding proteins on MDRl expression is 
opposite. These suggested an antagonistic effect of PTB and IMPl in controlling the 
level of HI9 and MDRl through an unknown mechanism. Other RNA binding 
protein(s) might also be associated with the HI9 RNA to form an RNA-protein 
complex. By UV-crosslinking assay, at least four proteins have been shown to bind 
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HI9 RNA directly or indirectly (perhaps through protein-protein interactions). One 
of the RNA binding proteins was identified as the hnRNP M protein (Chapter 4). 
Isoform of this protein can be expressed on the plasma membrane and binds to CEA 
(carcinoembryonic antigen). The role of hnRNP M protein in the HI9 downstream 
pathway needs to be further investigated. 
While PTB might regulate H19/MDR1 expression in the context of drug 
resistance, it is also demonstrated to regulate apoptosis by changing the level of 
pro-caspase-9 and Bcl-2 (Chapter 5). Therefore, PTB knockdown cells were 
generally more apoptotic when cells were treated with apoptosis inducers. The role 
of PTB in apoptosis has been implicated by its ability to regulate several apoptosis 
gene such as Apafl, Fas, caspase-2 and in this study, caspase-9 and Bcl-2. 
6.3 Unanswered questions and future work 
There are many questions raised and still left unanswered after this study. 
Therefore, future work might be done to address these questions and help us to have 
a better understanding in the field of ncRNA-mediated regulation. 
In chapter 4, it was shown that HI9 RNA could interact with cellular proteins to 
form a bulky complex. But the purpose or the function of such complex is unknown. 
One approach to understand the function of an RNA-protein complex is to identify 
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its individual components. This approach has been attempted and one of the possible 
components, although not yet been confirmed, would be hnRNP M. Two isoforms of 
hnRNP M has been identified by other groups. One being a nuclear protein while the 
other being a membranous protein that is able to bind CEA, a carcinogenesis marker. 
Further studies might focus on: 
Firstly, confirmation of the in vivo interaction of HI9 RNA with hnRNP M. 
This can be done by immunoprecipitation method. Immunoprecipitation of hnRNP 
M proteins followed by isolation of any bound nucleic acids from the complex could 
be performed by routine protocols. The isolated nucleic acids could be sequenced or 
more conveniently, probed with radiolabeled HI9 probes by Northern blot analysis. 
This can confirm the interaction of HI 9 with hnRNP M in vivo. 
Secondly, isolation of other HI9 interacting partners. Perhaps, a better method 
can be developed to isolate the RNA-complex formed in vivo. One of the in vivo 
methods has been suggested in the section of discussion in Chapter 4. In vivo 
methods have advantage in reducing non-specific binding as well as the reflection of 
real interaction environment. However, development of such in vivo system requires 
preparation of quite a lot of materials before the isolation procedure could be 
performed. 
Thirdly, assembly and localization of the RNA-protein complex in cells. A good 
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imaging method could be designed to trace the process of the RNA-protein complex 
assembly and subcellular localization. Studying the dynamic process of assembly and 
localization will help us to understand the molecular mechanism. While it is mostly 
accepted that HI9 RNA appears in the cytoplasm, we are also interested to know 
whether HI9 RNA will localize to the peripheral or surface region of the cells, as in 
consistence with the subcellular localization of hnRNP M long isoform protein. 
Finally, the functional activity of the RNA-protein complex. This might be the 
most difficult approach as the function of HI 9 has not been well-defined. Functional 
assay of RNA-protein complex could be performed by using in vitro method, 
provided that the function of the complex has been well defined. In the case of 
studying siRNA mechanism, functional siRNA-protein complex (RISC) was isolated 
from cell lysates and the functional activity was assessed by measuring the ability to 
degrade target mRNA. The wisdom can be applied to study HI9，after all, when HI9 
have well-defined functions. 
All the efforts aim at understanding why non-coding RNA like HI9 has 
functions. In recent ten years, research on non-coding RNA is blooming. Despite its 
growing interests captured, methodology in studying ncRNA is still developing. This 
is not only due to the fragility of RNA, but also due to limited knowledge on the 
understanding of RNA networking. Perhaps, the term "RNA signaling" will become 
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a standard glossary in the future biochemistry textbook, in addition to “protein 
signaling". 
6.4 A proposed model for HI9 pathway 
In order to explain the regulatory function of HI9 RNA in cells, a model of 
riboregulation was proposed to explain the regulatory function of HI9，based on the 
information provided in this study and other published papers. Firstly inside nucleus, 
the HI9 pre-RNA is spliced, 5'-capped and 3’ polyadenylated, just like other mRNA 
transcripts (Brannan et al. 1990). The mature HI9 RNA might interact with PTB to 
form a stable complex for nuclear transport. PTB has been implicated as an RNA 
chaperone to stabilize RNA structure (Song et al. 2005) and help the export of RNA 
from the nucleus to cytoplasm (Kamath et al. 2001). Therefore, genetic knockdown 
of PTB might destabilize HI9 RNA and decrease the cellular HI9 RNA level 
(Chapter 3). In cytoplasm, H19 RNA binds to IMPl in competition with PTB (Runge 
et al. 2000). If IMPl binding is dominant, less PTB can “protect，’ H19 RNA from 
degradation. Therefore, knockdown of IMPl allows more “protection，，of HI9 RNA 
by PTB and thus increases the cellular HI9 RNA level (Chapter 3). Formation of 
RNA-protein complex might favour recruitment of other cellular factors like hnRNP 
M (Chapter 4). Cellular factors might be recruited to the complex by RNA-protein 
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interaction or protein-protein interaction. The functional RNA-protein complex 
might finally enter the nucleus and regulates gene expression, most probably in 
transcriptional level. Non-coding RNA-directed gene transcription is modulated by a 
process called RNA-directed DNA methylation (Bayne & Allshire 2005; Castanotto 
et al. 2005; Mathieu & Bender 2004). This is one of the possible mechanisms that the 
RNA component of the complex directs other functional components such as DNA 
methyltransferase (Aufsatz et al. 2002) or transcriptional factors (Mattick 2003) to 
the promoter regions of the regulated genes. Therefore, HI9 could regulate MDRl 
transcription by altering the DNA methylation status in the MDRl promoter region. 
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Figure 6.1 A proposed model for HI9 pathway. In nucleus, PTB binds to mature 
HI9 RNA and facilitates its folding. The RNA-hnRNP complex is exported from 
nucleus to cytoplasm, in where HI9 RNA is associated with IMPl or other 
cytoplasmic interacting partner(s). Cytoplasmic HI9 RNA might interact with 
hnRNP M or indirectly with CEA to form a bulky complex. The bulky RNA-protein 
complex might finally localize to the nucleus and control DNA methylation in the 
promoter region of MDRl and perhaps other genes by RNA-directed DNA 
methylation. 
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